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HO-1 . . . . . . . . . . . heme oxygenase-1
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1 Introduction
1.1 Research on adipogenesis: historical background
Adipogenic precursor cells, so called preadipocytes, have been receiving increasing atten-
tion in the context of obesity, type-2-diabetes and other uprising diseases of the well-
nourished western hemisphere [1]. In order to understand fat neo-formation, energy ho-
meostasis, and adipose tissue physiology, preadipocytes have become an attractive tool
for researchers. The first immortal cell line of preadipocytes was created by Green and
colleagues [2] in the early 1970s. Around 1980, fat cells were mainly seen as a depot
for the storage of energy while the process of storing or releasing lipids was managed by
hormones [3–5]. The notion that indeed fat cells themselves are actively interfering with
the energy homeostasis of the human body emerged over the last decade: novel molec-
ular approaches discovered signaling molecules such as TNF-α, leptin, or plasminogen
activator-1 to be produced by adipocytes and highly influencing fat metabolism in an
autocrine and paracrine manner [6–11]. One of the most important approaches of this
decade was the demonstration of the multipotent character of human preadipocytes: after
adequate hormonal activation, they are able to differentiate into osteoblasts, endothelial
cells, myoblasts, chondrocytes and several other cell types [12–17]. However, the most
natural branch of differentiation in preadipocytes remains the adipogenic one.
Another pivotal aspect of research on adipose tissue has been pursued in this decade: the
reconstruction of subcutanous fat tissue in patients with soft tissue defects. These defects
may result from post-traumatic defects after extensive burns, tumor defects, or congenital
deformities [18]. Thus, there is an urgent need to find new approaches and techniques to
restore the missing tissue because of its protecting and modeling attributes representing
a mechanical cushion for muscles, tendons, and bones [18].
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1.2 Preadipocytes: a tool for adipose tissue engineering
1.2.1 Problems and limits of soft tissue engineering
Techniques of reconstructing soft tissue defects have been established in plastic surgery
over the last few decades and involve local and free flaps, dermal fat grafts, collagen
injections, the use of synthetic materials, and free adipose tissue grafts [18,19]. Disadvan-
tages such as foreign body reactions appear especially in methods using synthetic materi-
als whereas biologically derived transplants often shrink to an unpredictable extent [20].
Also, fat injection has not yet presented satisfying results [21]. Unfortunately, free adi-
pose tissue grafts are almost completely absorbed and replaced by fibrous tissue and oil
cysts [22, 23]. This is due to an insufficient vascularization and blood supply, causing
central hypoxia and cell necrosis [24]. A more promising way of reconstructing soft tissue
defects could be the embedding of autologous progenitor fat cells in biological scaffolds.
This method has become a well-studied field of research in the last years [19, 25,26].
1.2.2 Application of preadipocytes for soft tissue engineering
The exact definition of preadipocytes remains unclear: recent studies analyzed surface
antigenes in order to find an appropriate marker for the cell group of adipogenic precursors.
These cells belong to the so called stromal-vascular fraction of adipose tissue [27]. They
are able to differentiate into a variety of cells including endothelial cells, osteoblasts,
myoblasts, chondrocytes, and fat cells [12, 13, 17]. Unfortunately, a specific marker for
adipose progenitor cells has not been found yet which outlines the difficulty of exact
characterization. Since this is a broad field of study, my thesis will refer to adipogenic
precursors as preadipocytes. The focus of this thesis was the differentiation process of
fibroblast-like adipose progenitors to lipid-filled mature adipocytes suggesting that the
main componend of isolated cells is able to convert into adipocytes and can therefore be
called ”preadipocytes”.
Preadipocytes are considered a reservoir for new fat formation since in contrast to mature
fat cells, they have the ability to proliferate and differentiate into adipocytes [28] after
appropriate stimulation. Their putative role in soft tissue engineering can be explained
by their good ability to divide and be grown in cell culture as well as their good resistance
against nutrient and oxygen shortcome compared to mature adipocytes [29]. In 1999,
Patrick et al. introduced a polylactic-coglycolic acid (PLGA) polymer disk as a matrix
for preadipocytes. Since then, various scaffolds and non-wovens with varying materials,
porosity, and size have been created and examined [18,19,26,30–32]. In 2005, Hemmrich
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et al. presented an in vivo model of human preadipocytes seeded on hyaluronic-acid
based scaffolds which were implanted into immunodeficient mice. Their results were
encouraging since human preadipocytes were able to survive transplantation and even
showed extensive differentiation at the recipient site and vascularization of the surface [33].
However, there is still an urgent need to improve differentiation of preadipocytes especially
in larger implants in vivo. An insufficient differentiation causes cell necrosis and fibrotic
tissue. A transplanted preadipocyte-loaded scaffold with these attributes will not meet
the requirements for modeling and refilling extensive soft tissue defects. In vitro studies
on optimizing preadipocyte culture and differentiation are therefore the basis for further
in vivo experiments on preadipocyte-loaded scaffolds.
1.3 Mechanisms in adipogenesis
1.3.1 Preadipocyte proliferation and differentiation
In order to optimize preadipocyte culture and differentiation, the underlying physiolog-
ical processes need to be well understood. The two main steps involved in adipogenesis
are proliferation and differentiation of progenitor fat cells. Differentiation is the transi-
tion from undifferentiated fibroblast-like preadipocytes into mature round lipid-filled fat
cells [34] (Fig. 1.1). Proliferating preadipocytes undergo growth arrest initiated through
contact inhibition. Following growth arrest, preadipocytes must receive an appropriate
combination of mitogenic and adipogenic signals to continue through the subsequent dif-
ferentiation steps, leading to the progressive acquisition of the morphological and biochem-
ical characteristics of mature adipocytes [35]. This model postulates that proliferation of
preadipocytes occurs prior to differentiation. Indeed many studies using cell lines such
as 3T3-L1 preadipocytes [36, 37] came to this conclusion, whereas studies using human
preadipocytes indicate that partially differentiated cells remain capable of replication [38].
In their fully differentiated state, adipocytes are incapable of cell division although there
have been some reports of the replication of mature adipocytes in vitro [39, 40].
1.3.2 Signaling cascades
In vitro studies show that preadipocyte proliferation and differentiation are defined by
intrinsic and extrinsic factors including adipose depot, donor age, and androgen or estro-
gen status [41–43]. In cell culture, hormonal stimulation of the differentiation process has
been extensively investigated [28, 40, 44, 45]. Differentiation of confluent preadipocytes
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Figure 1.1: Schematic representation of the major processes of adipogenesis. Deriv-
ing from mesenchymal stem cells, preadipocytes represent a cell group of the stromal-vascular
fraction in the adipose tissue. After hormonal stimulation, preadipocytes proliferate (in vitro
until confluency) before the process of differentiation can be induced. During differentiation,
the cells collect lipid vacuoles until they become all lipid-filled mature adipocytes.
is induced by hormones such as insulin, but also by glucocorticoids, phosphodiesterase
inhibitors, and others [44,45]. Fig. 1.2 - Fig. 1.4 illustrate the complex intracellular mech-
anisms. Transmembrane proteins such as insulin-like growth factor receptor (IGFR)-1
and members of the epidermal growth factor (EGF)-like protein family respond to extra-
cellular stimuli. These trigger intracellular cascades which induce or repress transcription
factors that modulate adipogenesis. Novel studies ascertain two kinase systems that are
activated by IGF-1 receptor signaling: MAP kinases and phosphatidylinositol 3-phosphate
protein-kinase B/Akt [46–48]. The latter inhibits the forkhead transcription factor Foxo
1 (FKHR) which was recently discovered to lower the activity of PPARγ, one of the key
regulators in adipogenesis [48–52]. Lipophilic substances such as glucocorticoids, insulin
sensitizers, and others directly interact with cytosolic receptors thereby influencing gene
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Figure 1.2: Hormonal induction of adipogenesis. Intracellular cascades which influ-
ence pro-adipogenic transcription factors are triggered by metabolic regulators such as insulin,
dexamethasone, and IBMX. Insulin-induced activation of the IGF-receptor induces pathways
involving MAP kinases and PIP-kinase B/Akt. Glucocorticoids directly induce C/EBPβ and
bind to an intracellular receptor which activates other transcription factors. IBMX promotes
differentiation via unspecific inhibition of phosphodiesterases which leads to higher cAMP lev-
els. cAMP acts through protein kinase A targeting the cAMP element binding protein (CREB).
CREB induces expression of C/EBPβ (also activated by GSK3β, PKC, and MAPK) which
stimulates adipogenesis via induction of PPARγ.
transcription (compare Fig. 1.2). Apart from direct interaction with their intracellular
receptor which targets specific DNA-sequences, glucocorticoids have recently been shown
to induce C/EBPβ, a transcription factor at an early state of adipogenesis [53]. C/EBPβ
is one of the key regulators of adipogenesis and is also induced by an intracellular cascade
which is set off by isobutylmethylxanthine (IBMX) [28]: the IBMX-induced inhibition of
phosphodiesterases (PDEs) elevates adenylyl monophosphate (cAMP)-levels which even-
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tually target specific binding proteins (CREBs) [28]. CREBs can also be activated by
PKC, MAPK, and GSK3β [54–56]. The DNA-binding capacity of CREB is most likely
activated by hyperphosphorylation [57]. At the end of the cascade, C/EBPβ and C/EBPδ
induce the expression of PPARγ which in turn activates C/EBPα [28]. These two pro-
teins are the central transcriptional regulators of adipogenesis targeting adipocyte-specific
genes [58]. The protein ADD-1/SREBP-1c accelerates adipocyte differentiation, regulat-
ing the expression of PPARγ, and providing ligands for this receptor [59, 60] (Fig. 1.3).
PPARγ as well as ADD-1/SREBP-1c and C/EBPα are therefore useful adipogenic mark-
ers for PCR or western blot analysis.
C/EBPß
ADD1/SREBP1
PPARγ
C/EBPδ
Ligand
RXRα C/EBPα
Fat cell-specific gene expression
Hormonal 
stimulation
Figure 1.3: Major transcription factors involved in preadipocyte differentiation.
Hormonal induction of transcription factors promotes the differentiation process. Early tran-
scription factors, C/EBPβ and C/EBPδ, induce PPARγ which (in complex with RXRα) ac-
tivates C/EBPα, thereby maintaining differentiation by feedback mechanisms. Another tran-
scription factor, ADD-1/SREBP-1c, activates PPARγ by producing an endogenous ligand and
by inducing its expression [figure modified after Rosen and Spiegelman 2000].
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The complex network of adipogenesis can be influenced at many sites where extra- or intra-
cellular stimuli interfere with the cascades described above. One example can be given by
the family of heat shock proteins (HSP): HSPs generally serve as intracellular chaperones,
thereby controlling protein folding [61]. However, recent literature found evidence that
they also interact with adipogenic processes: HSP70 and HSP90 were demonstrated to
build complexes with glucocorticoid receptors and the peroxisome proliferators-activated
receptor prior to ligand activation [61–63] (Fig. 1.4).
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Figure 1.4: Role of heat shock proteins in adipogenesis. HSP70 and HSP90 build
complexes with glucocorticoid receptors and PPARγ. Polymorphisms of both HSPs are linked
to an increased risk for obesity and type 2 diabetes. HSP27 influences insulin sensitivity by
chaperoning IGF-1 and Akt.
The relevance of this can be concluded from clinical studies which have linked polymor-
phisms in HSP70 to an increased risk for obesity and type 2 diabetes [64,65]. Furthermore,
HSP27 interacts with the insulin-like growth factor receptor 1 and its signal transducer,
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the serine/threonine kinase protein Akt, thereby influencing insulin sensitivity [66, 67]
(Fig. 1.4).
1.3.3 Mitochondrial reactive oxygen species formation
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Figure 1.5: Mitochondrial ROS generation. The mitochondrial electron transport chain
consists of different complexes (I-V). NADH carries protons (H+) and electrons (e-) to the elec-
tron transport chain located in the inner membrane. The energy from the transfer of electrons
along the chain transports protons across the membrane and creates an electrochemical gradi-
ent. As the accumulating protons follow the electrochemical gradient back across the membrane
through complex V (ATP synthase), the movement of the protons provides energy for synthe-
sizing ATP. At the end of the electron transport system, two protons, two electrons, and half
of an oxygen molecule combine to form water. A small percentage of the O2 consumed by this
transport chain is incompletely metabolized and reduced to superoxide anions (O·−2 ) which are
subsequently diverted into other ROS such as H2O2 by complex I and III. Propofol inhibits
complex I and also scavenges free radicals at this site.
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Besides appropriate hormonal stimulation [68], the cellular redox status regulates the bal-
ance between proliferation and differentiation in most cell types [69]. Even cell-extrinsic
signaling molecules like growth factors have been demonstrated to induce extensive pro-
genitor self-renewal by changing the intracellular redox state. In general, free radicals can
cause severe damage to biological systems: increased levels of oxidative stress are associ-
ated with inhibition of tumor growth, blockade of cell cycle progression and induction of
apoptosis [70,71]. The concept of mitochondrial reactive oxygen species (ROS) generation
is as follows: mitochondria, which have been recognized to be involved in adipose tissue
plasticity [72], constitute the primary source of ROS generation in many cells. The outer
mitochondrial membrane contains complexes of integral membrane proteins that form
channels through which a variety of molecules and ions can pass. The inner membrane
contains 5 complexes of integral membrane proteins (Fig. 1.5): NADH dehydrogenase
(Complex I), succinate dehydrogenase (Complex II), cytochrome c reductase (Complex
III; also known as the cytochrome b-c1 complex), cytochrome c oxidase (Complex IV), and
ATP synthase (Complex V). In cellular respiration, energy is obtained through the trans-
fer of electrons down the electron transport chain. Electrons are removed from an electron
donor (NADH or FAHD2) and passed down the electron transport chain to a terminal elec-
tron acceptor (O2) via a series of redox reactions (Fig. 1.5). Complexes I, III, and IV use
this energy to pump protons from the mitochondrial matrix into the intermembrane space.
Figure 1.6: Schematic representation of
manganese superoxide dismutase of hu-
man mitochondria
The resulting transmembrane proton gra-
dient is used to make ATP via ATP syn-
thase. As can be seen from Fig. 1.5, a small
percentage of the consumed O2 is, however,
incompletely metabolized and reduced to a
superoxide anion radical (O·−2 ) by complex
I and complex III according to their steady
state reduction [73]. Propofol is able to in-
hibit complex I and scavenge free radicals
at this site [74] (see Fig. 1.5). Superoxide
anions are diverted into secondary prod-
ucts such as hydrogen peroxide (H2O2) by
superoxide dismutases (SOD).
Superoxide dismutases were first discovered in 1969 by McCord and Fridovich [75] and
prevent the intracellular accumulation of radicals. In mitochondria, these enzymes have
a manganese ion (Mn) in their active center (Fig. 1.6) whereas cytosolic and intracellular
variants hold copper/zinc (Cu/Zn) centers. The reduced form of the metal (MnII or CuI)
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transfers superoxide anions to H2O2 (equation 1.1), followed by the oxidation of a second
equivalent of O·−2 through MnIII or CuII to O2 (equation 1.2) [76]. The less aggressive
H2O2 is degraded by other enzymes such as catalases and glutathione peroxidase.
O·−2 +M
n+ + 2H+ −→ H2O2 +M (n+1)+ (1.1)
O·−2 +M
(n+1)+ −→ O2 +Mn+ (1.2)
Net reaction:
2O·−2 + 2H
+ −→ H2O2 +O2 (1.3)
An endogenous overproduction of superoxide anions is linked to a reduced ability to
eliminate free radicals (= oxidative stress) and can cause severe damage to biological sys-
tems [77]. Thus, superoxide dismutases are already commercially available at pharmacies
praised to have anti-inflammatory and cell protecting abilities [76].
1.3.4 Oxidative stress and adipogenesis
In adipogenesis, free radical formation has been demonstrated to inhibit fat cell forma-
tion by reducing C/EBP binding capacity [78]. In particular, mitochondrial ROS are
substantially involved in adipogenic processes: ROS are linked to redox-sensitive signal
transduction activation such as MAPK and Akt that promotes the phosphorylation of
HIF-1α [79, 80] (Fig. 1.7). Phosphorylation increases the transcriptional activity of HIF-
1α via the dimerization with HIF-1β [81]. The heterodimer represses PPARγ promoter
activation [82] (Fig. 1.7) and activates the expression of transcription factors depending
on the cell type [81]. A second model for the anti-adipogenic effects of ROS was intro-
duced by Carriere [74, 83] and Galinier [84]: they found that hypoxia partially inhibits
mitochondrial electron transport, producing redox changes in the electron carriers that
increase ROS generation [74]. Hypoxia-dependent inhibition of adipocyte differentiation
was associated with an increase of HIF-1α, as expected, but they also found an inde-
pendent mechanism of ROS controlled expression of CHOP-1, a negative regulator of
C/EBPs, which forms heterodimers with these proteins (Fig. 1.7) [85]. These observa-
tions were supported by Galinier et al. [84] in experiments with Zucker rats: the adipose
tissues of obese individuals showed a specific higher content of hydrophilic molecules in a
lower redox state than those of lean rats indicating that obesity is associated with reduced
oxidative stress.
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ROS are also involved in insulin resistance of mature adipocytes by down-regulating
GLUT-4 expression [86]. The effects of HIF transcription factors on adipogenesis may,
however, be different under normoxia conditions: Shimba at al. recently demonstrated
that members of the C/EBP family are also able to induce HIF-2α [87, 88]. Under nor-
moxia, HIF-2α then acted as a promoter of adipogenesis by direct transcriptional activa-
tion of glucose transporters such as GLUT1 and GLUT4 [87,88] (Fig. 1.7). This leads to
improved cell metabolism and therefore favours preadipocyte differentiation.
glucose uptake
CHOP-10
C/EBPβ
HIF-2α
nucleus
cytoplasma
PPARγ
ROS
mitochondria
HIF-1α
HIF-1β
heterodimer
MAPK  
Akt
Hypoxia
induces expression
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activates
Figure 1.7: Intracellular modification of signaling pathways by reactive oxygen
species and hypoxia. Mitochondrial ROS highly influence adipogenesis, especially under
hypoxic conditions, via induction of CHOP-10, a negative regulator of PPARγ, down-regulation
of certain glucose transporters, and promotion of heterodimerization of HIF-1. The subsequent
transcriptional acitivity leads to repression of PPARγ promoter activation. Under normoxia,
C/EBPß induces HIF-2α, thereby enhancing cellular insulin sensitivity.
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In conclusion, the reduction of oxidative stress does not only promote the differentiation
process from preadipocytes to mature fat cells, it may also affect insulin sensitivity and
energy homeostasis in general [78]. Besides their potential to influence adipogenesis, ROS
are involved in the development of degenerative diseases and aging [89]. They can function
as physiological signaling molecules [90] and second messengers in the O2-sensing mech-
anism triggering gene transcription of erythropoietin and vascular endothelium growth
factor [91]. Various cytoplasmic enzymes such as HO-1 or SOD-1 respond to increased
ROS levels which emphasizes the specific gene-regulating properties of ROS inside the
cell.
1.4 Effects of nitric oxide
1.4.1 Intra- and extracellular effects of nitric oxide in the human
body
The signal molecule nitric oxide (NO) is a central mediator of multiple physiological and
pathophysiological functions throughout the body. NO is synthesized by the enzyme nitric
oxide synthase (NOS) from L-arginine and in the presence of molecular oxygen resulting in
equimolar concentrations of NO and citrulline. NO has a half-life of seconds and is usually
oxidized to the inactive but stable endproducts nitrite and nitrate (NO2 and NO
−
3 ) [92].
In this study, the donor-molecule DETA (dietylentriamin) that releases NO for 24 hours
was used to provide a continuous concentration of NO in the culture medium.
There are several isoforms of the NOS enzyme that have been isolated and studied: two
of them are constitutively expressed NO synthases: endothelial and neuronal NOS (eNOS
and nNOS). Endothelial derived NO is best known for its function as a regulator of the
vascular tone [93]. Neuronal NO has important functions in the central nervous sys-
tem such as formation of memory [94]. Furthermore, NO can act as a neurotransmitter
causing relaxation in the gastrointestinal tract and the corpus cavernosum mediating pe-
nile erection which makes the combination of sildenafil - a competitive binding agent
of cGMP specific phosphodiesterase type 5 in the corpus cavernosum - and NO-donors
so dangerous [95–98]. Additionally, after activation by proinflammatory cytokines (e.g.
interleukin-1ß, tumor necrosis factor-α, interferon-γ, etc.) and/or bacterial products (e.g.
lipopolysaccharides (LPS)), an inducible NO synthase (iNOS) is expressed producing
NO for prolonged periods of time (hours to days) in an apparently unregulated fash-
ion [99, 100]. Intracellular NO-mediated signaling pathways are classified as either being
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cyclic guanylic acid (cGMP)-dependent or -independent. cGMP formation results from
NO binding to the heme group of soluble guanylyl cyclase, thus leading to enzyme ac-
tivation. The cGMP-independent mechanisms include inhibition of iron-sulfur centers,
DNA damage, polyadenosine 5’-diphosphate-ribosylation activation with cellular energy
deprivation, protein modification due to S-nitrosation of thiol groups, and, in the context
of concurrent oxidative stress, tyrosine nitration, which causes the antimicrobial, cyto-
static or cytotoxic effects of NO [101–104]. Yet, the picture of how NO influences signal
transduction remains complex and is far from being completely understood.
1.4.2 Nitric oxide and adipogenesis
With the identification of eNOS and iNOS in adipose tissue [105, 106], increasing recog-
nition has emerged for a regulating role of NO in fat cell formation: in 2002, Yan et al.
discovered an enhancement of differentiation in rat white adipose tissue [107]. Hemm-
rich et al. found that NO inhibits preadipocyte proliferation while promoting adipogenic
conversion to mature fat cells in vitro [108]. In vivo experiments linked NO to increased
insulin sensitivity of the white adipose tissue and inhibition of lipolysis in subcutaneous
adipose tissue depots [109–114]. In 2004, Engeli et al. found increased iNOS expression
in adipogenic differentiation and proposed NO to be an important mediator in adipocyte
physiology with lipogenic abilities [115]. Since iNOS is a key effector enzyme of in-
flammation (see section 1.4.1), it drives NO production after activation and therefore
reinforces and maintains the inflammatory response [116]. Further, an increasing body
of evidence has emerged that inflammatory processes are linked to the formation of adi-
pose tissue: a state of chronic low-level inflammation with raised plasma levels of in-
flammatory cytokines and acute-phase proteins is found in obesity and the metabolic
syndrome [117–121]. Increased plasma levels of cytokines and acute-phase proteins lead
in turn to an up-regulation of iNOS gene expression [115] which promotes further adipose
tissue formation by enhancing lipid storage and by decreasing basal and catecholamine-
induced lipolysis [109–114,122,123].
1.4.3 Possible modulation of preadipocyte differentiation in soft
tissue engineering
Preadipocytes are potential targets of eNOS- or iNOS-synthesized NO. Effects of NO
on preadipocytes are rarely characterized to date [107]. The direct link between NO
and adipogenic precursor cells is the unavoidable inflammatory response which will ap-
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pear in every setting of implanted cell-loaded scaffolds for reconstruction purposes. As
mentioned above, a present focus of attention in tissue engineering is the insufficient mat-
uration of preadipocytes, especially in the center of larger three-dimensional constructs.
The reason for this is not yet completely understood. Although insufficient blood and
oxygen supply are suspected to be the main reasons, inflammation might be a so far un-
derestimated factor. In order to analyze effects of NO on preadipocytes in a setting as
found after transplantation of a three-dimensional cell-seeded biohybrid, primary human
preadipocytes were treated with DETA/NO and NO-mediated effects on proliferation and
adipogenic conversion was investigated. Possible intracellular mechanisms are described
in Fig. 1.8. Besides NO, modulators of adenylyl and guanylyl cyclases - two enzymes
which play a major role in the differentiation process - and cAMP and cGMP-analogues
were examined for their potential to enhance preadipocyte differentiation (see Fig. 1.8).
I looked at the specific ability of each substance to modulate the differentiation process
and combined activators of both cyclases with NO and cAMP/cGMP-analogues. Specific
inhibitors of both enzymes (ODQ = guanylyl cyclase inhibitor and DDA = adenylyl cy-
clase inhibitor) were added separately and combined in order to elucidate the NO-effect on
guanylyl cyclase as well as adenylyl cyclase. In a second step I tried to modify the standard
medium (DMEM/Ham’s F12 + IBMX, pioglitazone, transferrin, dexamethasone, insulin,
and triiodo-L-thyronine) by omitting certain reagents and adding guanylyl/adenylyl cy-
clase activators and cGMP/cAMP-analogues. I therefore tried to facilitate and enhance
the differentiation procedure of preadipocytes which lasts about 14 days under standard
medium conditions. A modified culture medium and a thorough understanding of the
intracellular mechanisms could be useful in tissue engineering in terms of facilitating
preadipocyte differentiation in three-dimensional carriers in vitro before implantation or
in already implanted transplants by hormonal stimulation in vivo.
1.5 Pharmaceutical modulation of adipogenesis
1.5.1 Clozapine-induced weight gain: clinical relevance and possible
mechanisms
If adipogenesis can be influenced by various hormones and transmitters, the question
arises of whether certain drugs that cause weight gain in patients - such as atypical neu-
roleptics, lithium chloride, or antidepressants - can have a direct influence on preadipocyte
maturation as well. With atypical neuroleptics, the exact mechanisms of increased weight
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Figure 1.8: Intracellular effects of nitric oxide, activators, and inhibitors of
adenylyl cyclase and guanylyl cyclase. As in other cells, nitric oxide may act through
guanylyl cyclase in preadipocytes, too. However, also adenylyl cyclase activation has to
be considered as a potent intracellular signaling cascade. ODQ inhibits cytosolic solula-
ble guanylyl cyclase (csGC). Forskolin is an activator of membrane bound adenylyl cyclase
(AC); 2’-5’-Dideoxyadenosine (DDA) inhibits this enzyme. IBMX unspecifically inhibits
cGMP-phosphodiesterase (cGMP-PDE), cGMP-induced cAMP-phosphodiesterase (PDE-II),
and cGMP-inhibited cAMP-phosphodiesterase (PDE-III) thereby elevating intracellular cGMP
and cAMP levels [124]. Both cGMP and cAMP activate protein kinase G 1 and 2 (PRKG1,
PRKG2) and cGMP-dependent protein kinase (cGK) which then phosphorylate transcription
factors promoting adipogenesis. cAMP also activates specific PPARγ ligands (see Fig. 1.2 and
Fig. 1.3).
in patients is not yet fully understood. Among the atypical neuroleptics, olanzapine and
clozapine show the greatest weight-increasing potential [125, 126]. This weight gain sta-
bilizes in the short to medium term but often continues beyond the first year, leading
to weight increases of up to 20-30 kg [127]. The treatment-emergent weight gain has
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been beneficial in observing and anticipating the therapeutic effect of neuroleptics in pa-
tients [128]. However, adverse health effects such as cardiovascular diseases and insulin
resistance as well as psychological problems bear a risk for the physical health of the
patient. These side-effects may lead to frustration and non-compliance and therefore jus-
tify an intensive examination of the mechanisms responsible for the neuroleptics-induced
weight gain. One common hypothesis for the pro-adipogenic effect of clozapine involves
the hormone leptin, which is produced mainly in white adipose tissue and plays a major
role in the regulation of energy homeostasis and food intake by targeting the leptin recep-
tor in the hypothalamus [129]. Supporting this hypothesis, clozapine has been found to
increase serum leptin levels within days after starting treatment [130]. Thus, the percep-
tion of satiety is impaired and patients experience a lower suppression of appetite after
meals [131]. Other studies focussed on plasma levels of insulin, adiponectin, ghrelin and
even nitric oxide [132–135]. Unfortunately, these studies present controversial results con-
cerning plasma levels of such hormones involved in energy homeostasis. To extend the
understanding of the pathophysiology of clozapine-induced weight gain, the question of
whether preadipocytes are a target for clozapine has to be thoroughly analyzed. It might
lead to the insight that the increase in weight is a neo-formation of adipose tissue from
precursor cells.
1.5.2 Effects of clozapine, lithium chloride and propofol on
adipogenesis
Pro-adipogenic side effects in pharmaceuticals often cause adverse health effects and have
a negative influence on the patient’s compliance (see section 1.5). Unfortunately, the ex-
act mechanisms of how these drugs interfere with lipid regulatory mechanisms are poorly
understood. As in atypical neuroleptics, the pro-adipogenic effects, especially of clozapine
and olanzapine, are controversially discussed in the literature [129,130,132–135]. However,
a detailled analysis of intracellular clozapine-effects in preadipocyte maturation has not
been given yet. Imaginable is an induction of adipogenic genes by intracellular cascades
as observed for IBMX, insulin, or glucocorticoids (see section 1.3.2). Indeed, some studies
describe the involvement of guanylyl cyclase (as in nitric oxide-mediated cascades) and
dopamine-receptor mediated activation of adenylyl cyclase in the context of clozapine in
neurons and other cell types [136–138]. The effects of clozapine inside the cell could also
be explained by the contrary mechanism of superoxide production and peroxide scaveng-
ing, as recently demonstrated for radical scavengers such as propofol [74, 83]. Propofol,
a commonly used sedative and anesthetic agent, is chemically similar to the endogenous
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antioxidant α-tocopheral (vitamin E) [139], and has demonstrated antioxidant functions
at organ and cellular levels: it efficiently attenuates oxidant injury in myocardial tissue,
mitochondria, brain synaptosomes, and erythrocyte membranes [140–143]. That is why
propofol is especially useful for anesthesia in patients with critical illnesses who are un-
dergoing surgery that abnormally enhances oxidative stress [144, 145]. Its anti-oxidant
and free radical-scavenging abilities lead to reduced generation of mitochondrial reactive
oxygen species [74]. As mentioned above, every change in the sensitive balance of the
intracellular redox sytem can cause severe alterations of gene transcription and set off
intracellular cascades. Carriere et al. postulated that the propofol-induced reduction of
ROS-generation causes increased preadipocyte differentiation [74, 83]. This led us to the
assumption that the clozapine-effect might be due to similar mechanisms which became
the basis for our study design.
1.5.3 Green tea: a potential remedy?
Green tea is a widely-consumed beverage in Asia and has been regarded to have health-
promoting effects for centuries [146]. During the last decade, the traditional notion that
green tea consumption causes beneficial health effects has received scientific attention and
became the focus of intensive research [147–150]. Green tea and its main active compo-
nents, the catechins, of which EGCG is the most abundant [148, 151], is said to have
beneficial health effects due to its antioxidant activity leading to protection of organs
systems, tissues, and cells from damaging free radicals [152]. EGCG has demonstrated
anti-atherogenic and anti-coagulatory effects in various contexts [147, 153, 154]. Studies
show that the polyphenols in green tea reduce the risk of cancer at several sites by stim-
ulating the production of immune system cells [155]. Interestingly, EGCG is also known
for its weight-reducing abilities which are due to metabolic and intracellular effects: there
are reports on EGCG-mediated glucose uptake inhibtion by competitive inhibition of
sodium/glucose cotransporters [156], reduced α-amylase and sucrase activities [157], and
inhibition of gastrointestinal enzymes involved in nutrient digestion [146]. EGCG is also
known to reduce levels of adipogenesis-related transcriptional factors, such as C/EBPß and
PPARγ [158], and to suppress the activation of enzymes responsible for lipid metabolism,
e.g. sterol regulatory element binding protein-1, in adipose tissue [159]. Various studies
show that EGCG reduces size and number of lipid droplets and GPDH-activity in dif-
ferentiating preadipocytes [160]. This effect can be explained by the above mentioned
reduction of adipogenic transcriptional factors. Since EGCG has been found to liber-
ate H2O2 [161], its effect on cytotoxity and especially tumor growth has been extensivly
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studied: the free radical H2O2 inhibits growth of tumor cells by oxidative stress, block-
ing cell cycle progression, inducing apoptosis or causing necrosis in a dose and cell-type
dependent manner [70]. Evidently, the susceptibility to EGCG is cell type specific and
depends on the cell’s ability to maintain its redox balance [71]. Normal human ker-
atinocytes, for example, are capable of reducing oxidative stress and are therefore less
susceptible to damage [162]. Referring to these findings and trying to find a link between
anti-adipogenic effects of EGCG in preadipocyts and hydrogen peroxide production, I
looked at the effects of EGCG on manganese superoxide dismutase which catalyzes the
reaction from superoxide anions to hydrogen peroxide. Moreover, Chan et al. recently
discovered, that EGCG can inhibit the growth of ovarian cancer cell by amplifying the
cytotoxic effect of cisplatin which is most likely due to enhanced intracellular H2O2 gen-
eration [162]. Thus, hydrogen peroxide generation represents another mechanism for the
anti-adipogenic effects of EGCG. Summarizing these observations, cellular redox status,
Mn-SOD activity, and hydrogen peroxide generation could explain intracellular effects of
EGCG as well as of clozapine. EGCG most likely promotes Mn-SOD expression thereby
influencing adipogenesis. Clozapine, however, could have an inhibitory effect on Mn-SOD
expression (see Fig 1.9). Supposing that EGCG might counteract the clozapine-induced
neo-formation of fat cells, drinking green tea could present an easy but effective way to
decrease neuroleptics-induced weight gain in patients.
1.6 Aim of this study
Examining and modulating preadipocyte proliferation and differentiation can be helpful
for adipose tissue engineering as well as for understanding and treating clozapine-induced
weight gain: in the first study, the role of NO in regulating proliferation and differenti-
ation of human preadipocytes was analyzed. To elucidate the intracellular mechanisms
of NO on preadipocyte differentiation, inhibitors and activators of guanylyl and adenylyl
cyclase and cGMP/cAMP-analogues were added to the culture media. The differenti-
ation medium was modified by omitting and adding certain reagents to find the most
effective combination with the least reagents in order to facilitate future differentiation
procedures. The results of this study are potentially helpful to modify present tissue
engineering applications in order to improve cell maturation and organization in three-
dimensional biohybrids.
The second study focussed on the effects of the neuroleptic clozapine on preadipocyte pro-
liferation and differentiation in order to find a new explanation for weight gain in patients
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Figure 1.9: Modulation of Mn-SOD activity by EGCG and clozapine. EGCG ac-
tivates Mn-SOD activity leading to higher intracellular peroxide-levels which inhibit differen-
tiation. Clozapine may act through inhibition of Mn-SOD thereby causing higher superoxide
anions levels thereby influencing preadipocyte proliferation and differentiation.
under long-term clozapine-treatment. Morphological changes and intracellular effects of
clozapine on preadipocytes were investigated. Furthermore, the particular combination
of clozapine and green tea was tested in order to determine its potential to decrease
preadipocyte differentiation.
1.7 Study design
Preadipocytes were grown in standard culture medium (DMEM/Ham’s F12) in vitro after
being isolated from human adipose tissue samples. Proliferation and differentiation was
evaluated separately and induced by common growth factors and hormones. Proliferating
and differentiating cells were treated with NO at varying concentrations applied in form
of a slow release carrier (DETA) which also served as a control to exclude any adipogenic
effects. Proliferation was assessed by cell counting and evaluation of absorption changes
due to mitochondrial conversion of a formazan dye (XTT-assay). Differentiation was mea-
sured via evaluation of enzyme activity of adipogenic conversion (GPDH-assay) and photo
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documentation. Our hypothesis was based on studies about rat preadipocytes in which
differentiation was highly promoted under NO addition [107]. We expected a rather
inhibiting effect of NO on preadipocyte proliferation according to their cell physiology
which favours either the proliferating or the differentiating branch. Intracellular effects of
guanylyl and adenylyl cyclase-dependent pathways were evaluated by inhibitors and pro-
moters of both enzymes as well as analogues of cAMP and cGMP. All conditions were also
treated with DETA/NO to reveal possible intracellular mechanisms and their potential
role in NO signaling. Assumed were strong participation of cGMP-dependent pathways
and minor effects of cAMP-dependent mechanisms according to the literature [163–165].
Culture media were subsequently modified with cGMP and cAMP-analogues to facilitate
and enhance culture conditions for preadipocyte differentiation.
The effect of clozapine on proliferating and differentiating cells was evaluated in a sec-
ond study. Propofol and LiCL served as controls. Propofol was previously described
to have a promoting effect on preadipocyte differentiation due to the reduction of ROS-
generation by Carriere et al. [74]. LiCl has pro-adipogenic effects which are rather due to
general metabolic activity such as increased glycogen synthesis [166] and glucocorticoid
elevation [167], thus having no direct influence on preadipocyte differentiation. Since I
assumed a promoting effect of clozapine on preadipocyte differentiation following similar
patterns as described for propofol [74, 83], EGCG was added to clozapine-treated condi-
tions in order to assess its potential ability to counteract the clozapine-effect by increased
hydrogen peroxide production. This effect was hypothesized to be caused by enhanced
Mn-SOD expression since EGCG has been reported to increase the activity of MnSOD in
human hepatoma HepG2 cells and murine large intestinal cancerous epithelium [168,169].
Proliferation and differentiation were again evaluated by the above mentioned assays
(XTT-assay, GPDH-assay), cell counting, photo documentation, and Oil-Red-O-staining
of fat vacuoles in differentiated cells. PCR-analysis of superoxide dismutases was per-
formed to evaluate activation of the MnSOD gene in EGCG-treated preadipocytes.
2 Materials and methods
2.1 Reagents
DETA was purchased from Aldrich (Taufenkirchen, Germany), collagenase solution
type I 0.2%, PBS, and fetal calf serum (FCS) were from Biochrom (Berlin, Ger-
many), triiodo-L-thyronine, transferrin, dexamethasone, basic fibroblast growth fac-
tor (bFGF), isobutylmethylxanthine (IBMX), 8-Br-cGMP, 2,5-dideoxyadenosine, 8-Br-
cAMP, forskolin, propofol, hydroethidine, propidium iodide, and EGCG were from
Sigma (Deisenhofen, Germany), 8-pCPT-cGMP was from Biolog (Bremen, Germany),
ODQ from Alexis (Gru¨nberg, Germany), pioglitazone from Takeda Pharmaceuticals
(Lincolnshire, USA), Dulbecco´s modified Eagle medium (DMEM), trypsin and peni-
cillin/streptomycin from PAA Laboratories (Colbe, Germany), lithium chloride (LiCl)
from Merck (Darmstadt, Germany), and clozapine from Novartis (Nuremberg, Ger-
many). The 250 µm-nylon sieve was from Verseidag Techfab GmbH (Geldern, Germany).
DETA/NO was synthesized and isolated as described [170]. The GPDH-assay kit was
from Takara (Otsu, Japan), the XTT-Kit from Roche (Mannheim, Germany), and the
RNA-Isolation-Kit, the RNase-free DNase Set, the Omniscript-Kit, and the Taq core-Kit
from Qiagen (Hilden, Germany).
2.2 Equipment
The ”HeraCell240” incubator from Heraeus was used for cell incubation. For sterile
working conditions all reagents were added under the laminar flow ”Uniflow UVUB1800”
from Uniequip. Microscopy was performed with a Zeiss microscope at 10x magnification.
Water bath and shaking bath were from Gesellschaft fu¨r Labortechnik mbH (GFL), the
vacuume system ”Vacusafe” from Integra Bioscience. Reagents were weighed with a
Sartorius precision scale and mixed with a magnetic stirrer from Heidolph. Centrifugation
was performed with a ”MinifugeT” centrifuge from Kendro and a ”2-16KC” centrifuge
from Sigma. Cell culture equipment such as pasteur pipettes was sterilized in the autoclave
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”Autoklav 2540” from Systec. Changes of absorption in assays were measured by the
ELISA-reader ”MRX” from Dynex Technologies.
2.3 Cell isolation and culture conditions
For cell culture we used 96-, 12-, and 6-well-plates from Falcon and 25 cm2 or 75 cm2
culture dishes from Greiner Bio-One. Pipettes (25ml and 10ml) were from Costar whereas
the 5ml-pipette was purchased from Techno Plastic Products (TPP). Pasteur pipettes
were from Brand, pipette tips from Eppendorf. Tubes were from Falcon and beakers from
VWR.
Preadipocytes were isolated from freshly excised human subcutaneous adipose tissue of
patients (age: 18-67 years) who underwent elective operations (e.g. abdominoplasty)
at the Department of Plastic Surgery and Hand Surgery - Burn Center of the University
Hospital Aachen. Fibrous tissue and visible blood vessels were removed, the adipose tissue
was minced and digested by collagenase solution type I (0.2%) at 37◦ C for 45 min with
constant shaking. The ratio of tissue to enzyme was 1:1. After filtration (250 µm), the
fat layer was removed and the cell suspension centrifuged at 720 G for 7 minutes. After
resuspension of the pelleted cells in DMEM/Ham’s F12 supplemented with 10% FCS,
0.1% bFGF, and 1% penicillin/streptomycin, cells were seeded onto 25 cm2 or 75 cm2
culture dishes and cultured at 37◦ C at 5% CO2. The next day, cells were washed three
times with NaCl before adding new medium. Afterwards, culture medium was changed
every 3-4 days including two washing steps with PBS.
Growth, expansion, and differentiation of preadipocytes were carried out as follows: cells
were grown to confluency in DMEM/F12 (1:1) supplemented with 10% FCS plus bFGF
(10 ng/ml) and 1% penicillin/streptomycin. After two washing steps with PBS, cells
were trypsinized for about 5 minutes. Medium (supplemented with serum) was added
to stop trypsin activity. The cell suspension was centrifuged at 350 G for 10 minutes;
the pellet was resuspended into medium. Cells were equally distributed onto 6-wells
(for differentiating cells: ∼900.000 cells/well) or 12-wells (for proliferating cells: ∼60.000
cells/well). Adipogenic conversion was then promoted for 8-14 d by changing medium
to DMEM/F12 (1:1) without serum addition, supplemented with 66 nM insulin, 100 nM
dexamethasone, 0.5 mM isobutylmethylxanthine (IBMX), 0.1 µg/ml pioglitazone, 1 nM
triiodo-L-thyronine, and 10 µg/ml human transferrin (standard differentiation medium).
After 5 days of incubation, medium was used as before but without IBMX. To evaluate the
influence of NO on proliferation and differentiation, DETA/NO was added 6 days at 50 -
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150 µM for proliferating and 5 days at 30 - 100 µM for differentiating cells. DETA/NO was
activated by addition of 500 µl PBS and 0.3 µl HCl (1 N) per 0.82 mg DETA/NO. As a
control, DETA was used at 150 µM or 100 µM, respectively. For identifying the underlying
molecular pathway the specific guanylyl cyclase inhibitor ODQ (15 µM), the cGMP-
analogue 8-Br-cGMP (1 mM), and the phosphodiesterase-stable cGMP-analogue 8-pCPT-
cGMP (1 mM) were applied. Involvement of adenylyl cyclase was analyzed by addition of
the specific adenylyl cyclase inhibitor 2’,5’-dideoxyadenosine (DDA) (25 µM), the cAMP-
analogue 8-Br-cAMP (1 mM) and the adenylyl cyclase activator forskolin (10 µM). All
reagents (except DETA/NO which had to be renewed on a daily base) were added every
second day following a change of culture medium to avoid accumulation and toxicity.
To evaluate the differentiation potential of preadipocytes, various differentiation-inducing
factors were added to the differentiation medium (compare Table 2.1). To evaluate its
influence on proliferation and differentiation, clozapine was added every second day at
concentration levels between 5 µM and 50 µM. Propofol (10 µM), LiCl (2 mM), and
EGCG (10 µM) were added every other day. The addition of all substances was stopped
after 5 days in differentiation medium.
Table 2.1: Variation of culture media. Medium 1 represents the standard differentiation
medium, media 2-6 vary in reagents but not in concentrations (same as in 1, see 2.3). Peni-
cillin/streptomycin was added to each one of the media at a concentration of 1%.
1 2 3 4 5 6
IBMX x x x x
Pioglitazone x x
Transferrin x x
Dexamethasone x x x x x
Insulin x x x x x
Triiodo-L-thyronine x x
2.4 Determination of proliferation
To determine the total number of viable preadipocytes, cells were detached from the dishes
by trypsin treatment for 2-5 minutes, stained with trypan blue, and counted under the
microscope in a Neubauer-chamber. To verify cell counting results, an XTT cell prolifer-
ation assay [171] was applied. The use of the tetrazolium salt XTT (2,3-Bis(2-methoxy-4-
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nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) allows to analyze cell proliferation,
cell viability, and/or cytotoxicity. Cleavage of the tetrazolium salt to formazan occurs via
the succinatetetrazolium reductase system in the mitochondria of metabolically active
cells. During this process, XTT, a yellow tetrazolium salt, is cleaved to a soluble orange
formazan dye (see Fig. 2.1). Formazan formation in the supernatant was analyzed by
Figure 2.1: Formation of formazan dye. Cleavage of tetrazolium salts by enzymes of cells
which are metabolically active lead to the formation of formazan crystals. Formazan formation
in the supernatant of proliferating cells changes absorption wave length and gives rise to the
amount of vital cells.
the ELISA-reader after treatment with 5 mg/ml XTT and incubation for 60 minutes at
37◦ C.
To determine the number of attached but necrotic cells, the trypan blue exclusion assay
was applied: 9 g NaCl and 5 g trypan blue were added to 100 ml aqua dest. to get a
5% trypan blue solution. PBS (0.36 ml) was added to 0.27 ml of the trypan blue solu-
tion before being pipetted onto proliferating preadipocytes grown on 12-well plates in 1
ml medium per well. After incubation for 3 minutes, cells were counted under the mi-
croscope at 10x magnification, thereby comparing viable unstained cells to blue-stained
necrotic cells.
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2.5 Determination of differentiation
2.5.1 Morphological analysis
Morphological cell analyses to determine the extend of preadipocyte differentiation were
performed using a phase-contrast microscope at a 10x magnification, counting cells in the
field of vision, randomly chosen. Five fields were counted. Main morphological criteria
for differentiation were an increasing number and size of visible lipid droplets as well as a
change in morphology from elongated contours to a round shape.
2.5.2 Determination of differentiation by glycerophosphate
dehydrogenase (GPDH) assay
To evaluate preadipocyte differentiation on a molecular level, changes in GPDH activity
were measured according to a method by Wise and Green [172]. GPDH is a molecular
key marker of adipogenic conversion which catalyzes the reversible conversion between di-
hydroxyacetone phosphate and glycerol 3-phosphate using NAD as a coenzyme. Glycerol
3-phosphate is one of the basic componends in triacylglycerol-formation when estered
with long-chain fatty acids. GPDH activity is known to rapidly increase in the differen-
tiation process from preadipocytes to adipocytes [173]. Changes in the absorption of the
coenzyme NAD after enzymatic reaction can be measured by ELISA-reading at 340 nm
which gives rise to GPDH activity. The used reagents derived from a kit system from
Takara. Cells were washed twice with PBS and cell lysis was induced by adding ”Enzyme
Extraction Buffer”. Afterwards, the lysate was diluted to two-fold by adding ”Dilution
Buffer”. Enzyme activity was calculated with the following formula supplied by Takara:
GPDH activity (units/ml) = OD340 x 2.06 x dilution ratio of the sample. Cellular protein
content was measured according to a method by Bradford [174] to adapt GPDH levels to
cell number.
2.5.3 Oil Red O staining
Oil Red O staining was performed according to a method by Zacarias et al. [175]. Mono-
layer cultures were washed with PBS and fixed with cold 10% paraformaldehyde and
incubated for five hours at 4◦ C. Oil Red O working solution (0.5 g in 100 ml isopropanol)
was added to culture flasks for two hours at room temperature. After washing, stained
cells were kept in 10% paraformaldehyde and examined by light microscopy.
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2.6 RNA isolation
Cells were cultured and differentiated in 6-well plates as described above. At day 10-14
of differentiation, RNA isolation was performed according to the ”RNeasy Mini Hand-
book” from Qiagen: cells were washed twice with PBS, lysated with ”RLT” buffer (after
addition of 10 µl β-mercaptoethanol per 1 ml buffer), homogenized with a ”QUIAshred-
der” spin column, and centrifuged at 10.000 G in a collection tube for 2 minutes. 600 µl
of 70% ethanol were added before applying 700 µl of the sample to an ”RNeasy” mini
column placed in a collection tube and centrifuged for 15 seconds at 8000 G. The flow-
through was discarded. 350 µl ”RW1” buffer was pipetted into the mini column, and
centrifuged for 15 seconds at 8000 G. To digest DNase, 10 µl ”DNase I stock solution”
was added to 70 µl ”RDD” buffer. This incubation mix was pipetted directly onto the
”RNeasy” silica-gel membrane, and placed on the benchtop for 15 minutes. Afterwards,
350 µl ”RW1” buffer was pipetted into the mini column, centrifuged for 15 seconds at
8000 G; the flow-through was discarded. After transferring the RNeasy column into a
new collection tube, 500 µl ”RPE” buffer was added to the column. After centrifugation
for 15 seconds at 8000 G, the flow-through was discarded. Another 500 µl ”RPE” buffer
were added to the tube which was centrifuged for 2 minutes at 8000 G. To elute the
RNA, the column was placed into a new collection tube and 30-50 µl RNase-free water
was given directly onto the column which was then centrifuged for 1 minute at 8000 G.
All steps were performed using RNase-free pipette tips and RNase-free water according
to the ”RNeasy Mini Handbook”. The RNeasy Kit and RNase-free DNase Set contained
all of the listed buffers, reagents, and tubes.
2.7 Reverse Transcription (RT) and Polymerase Chain
Reaction (PCR)
RT was carried out at 37◦ C for 60 minutes with oligo dT (15mer) as primer using the
Omniscript-Kit. The cDNA (500 ng each) was used as template for PCR, primed by using
oligonucleotides and conditions as shown in table 2.2. Extensive testing for each gene
product was performed, to ascertain that amplification was always in the linear range.
After amplification, PCR-products were subjected to electrophoresis on 1.8% agarose
gels. Bands were visualized by ethidium bromide staining. Densitometric analysis of the
visualized amplification products was performed using the GeneGenius documentation
and analysis software (Syngene Cambridge, UK).
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Table 2.2: Primer used for PCR.
Gene primer sequence ann. temperature cycles
GAPDH f: 5‘-CAACTACATGGTTTACATGTTCC-3‘ 60◦C 24
r: 5‘-GGACTGTGGTCATGAGTCCT-3‘
Mn-SOD f: 5‘-AACGCGCAGATCATGCAGCTGC-3‘ 55◦C 40
r: 5‘-CCCAGTTGATTACATTCCAA-3‘
Cu,Zn-SOD f: 5‘-ACGAAGGCCGTGCGTGCTGAA-3‘ 64◦C 40
r: 5‘-ACCACAAGCCAAACGACTTCCAGC-3‘
2.8 Statistical analysis
Data are given as arithmetical means ± SD. Statistical analyses were performed using
GraphPad 5.0 statistical software (GraphPad Inc., USA). GraphPad InStat was used to
calculate one-way ANOVAs to compare treatment variation, GraphPad Prism was used to
calculate two-way ANOVAs to determine differences between treatments at certain time
points. Given p-values are compared to standard proliferation or standard differentiation
conditions, respectively, using Dunett’s post-hoc test. Standard deviations (±) are given
throughout.
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3 Results
3.1 Toxicity of DETA/NO and DETA
To monitore the toxicity of DETA and DETA/NO on preadipoytes, cells were cultured as
described above for 6 days. DETA/NO or DETA were added every 24 hours at 50-150 µM.
The number of necrotic cells was analyzed every day by the trypan blue exclusion assay.
As can be seen from Fig. 3.1, the mean number of dead cells in the untreated control is
9.9% ± 1.5%. Highest toxicity levels were found with DETA/NO at 150 µM (15.1% ±
2.6%), however, these values are not significantly different from control values. Toxicity of
DETA/NO at a concentration of 100 µM and 50 µM was lower than found with 150 µM
(10.2% ± 2.8 and 9.2 ± 1.7, respectively). DETA applied at 150 µM showed no toxicity
(10.5 ± 2.1 necrotic cells) (Fig. 3.1).
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Figure 3.1: Toxicity of DETA/NO and DETA on preadipocytes. Preadipocytes were
cultured as described. DETA/NO and DETA were added every day at concentrations indicated.
The number of necrotic cells was analyzed every day by the trypan blue exclusion assay.
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3.2 Effect of NO on preadipocyte proliferation and
differentiation
In order to determine the effects of NO on proliferating preadipocytes, DETA/NO or
DETA were added at 50 µM, 100 µM, or 150 µM. Proliferation was evaluated every day
by cell counting. As shown in Fig. 3.2 A., there is an exponential growth in the control
group. In all DETA/NO-treated cells proliferation was strongly inhibited with only small
increases in cell number. This NO-mediated inhibition was concentration dependent with
lowest cell numbers at 150 µM DETA/NO and highest cell numbers at 50 µM DETA/NO.
Compared to the control, growth inhibition is significant at day 5 (p ≤ 0.05) and at day
6 (p ≤ 0.001) (Fig. 3.2 A.). In order to analyze whether the growth inhibitory effect was
caused by NO or the donor molecule DETA, preadipocytes were cultured as described
before for 7 days with daily addition of DETA (Fig. 3.2 B.). The XTT-assay confirmed the
exponential growth of the control group. Addition of DETA does not inhibit the growth
of preadipocytes but causes a slightly quicker proliferation than found in untreated cells.
However, this difference to control treatment did not reach significance.
To analyze the effect of NO on preadipoyte conversion during differentiation, DETA/NO
or DETA were added at concentrations indicated on confluent preadipocytes grown in
differentiation medium. The extend of differentiation in the control group varies between
17.5% and 27.3% differentiated cells (compare Fig. 3.3 A.). With DETA, no change in
the extend of differentiation was observed (Fig. 3.3 B.). In contrast, DETA/NO at 50 µM
and 100 µM increased preadipocyte maturation significantly (46.7% ± 4.2% differentiated
cells at 50 µM (p ≤ 0.01) and 45.9 % ± 7.2 % differentiated cells at 100 µM (p ≤ 0.01),
compare Fig. 3.3 C.,D.). Concentrations higher than 100 µM revealed toxic effects on the
cells after a few days. Analysis of GPDH was found to be in complete accordance with
microscopical evaluations (Fig. 3.4). DETA/NO added at concentrations from 30 µM to
100 µM increased preadipocyte maturation. This increase was significant for DETA/NO
from 50 µM to 100 µM (p ≤ 0.05) with a peak at 70 µM (Fig. 3.4).
3.3 Molecular signaling pathway of NO in preadipocyte
differentiation
To further determine the role of NO in preadipocyte differentiation and detect the under-
lying signaling pathway 70 µM DETA/NO was applied in combination with the guanylyl
cyclase inhibitor ODQ, cGMP-analogues (8-Br-cGMP and 8-pCPT-cGMP (PDE-stable)),
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the adenlyl cyclase inhibitor DDA, the adenylyl cyclase activator forskolin, and the cAMP-
analogue 8-Br-cAMP (Fig. 3.5). Even though this concentration of NO had caused the
strongest increase in adipogenic conversion (172.6% ± 35.2%), the presence of ODQ de-
creased the NO-mediated effect (33.5% ± 4.8% differentiated cells) below control levels
(standard differentiation), and the combination of ODQ and DDA had an even stronger
effect (22.1% ± 15.1%, p≤0.05). With DDA alone, differentiation is reduced to 47.97%
± 37.3%. NO addition antagonizes this effect in part (75.66% ± 15,95%). Applying the
activators of guanylyl and adenylyl cyclase pathways together with the standard differ-
entiation mixture, relative preadipocyte differentiation was increased to 187.8% ± 85.6%
(8-Br-cGMP), 166.5% ± 24.8% (8-pCPT-cGMP), 188.63% ± 65.84% (forskolin), 204.79%
± 81.05% (8-Br-cAMP), and 182.51% ± 45.97% (8-Br-cAMP+8-Br-cGMP) compared to
controls (set to 100%) (Fig. 3.5). With most activators of preadipocyte differentiation
(8-pCPT-cGMP, forskolin, and 8-Br-cAMP), NO-addition caused an even higher extend
of differentiation (p≤0.05) (see Fig. 3.5). The most effective combination to maximize
preadipocyte differentiation was 8-Br-cAMP + NO (256.0% ± 38.5% differentiated cells).
Interestingly, the combination of 8-Br-cGMP and NO did not promote differentiation
(73.8% ± 26.0 differentiated cells) which might be due to degradation of 8-Br-cGMP by
phosphodiesterases. When the phosphodiesterase-stable cGMP-analogue 8-pCPT-cGMP
was applied in combination with NO, differentiation increased to to 191.9% ± 16.0%
compared to standard differentiation (p=0.02). The combination of 8-Br-cGMP and 8-
Br-cAMP also promoted differentiation and NO addition further increased the adipogenic
conversion (p≤0.01).
3.4 Optimization of differentiation media
To facilitate culture conditions, the standard differentiation medium was modified with
the aim to optimize culture conditions with the least amount of differentiation inducing
factors. The standard differentiation medium consists of DMEM/Ham’s F12 plus the 6
reagents IBMX, pioglitazone, dexamethasone, transferrin, insulin, and triiodo-L-thyronine
(first 5 days, from then on without IBMX and pioglitazone). The number of factors was
reduced in different set-ups and replaced by other differentiation-promoting reagents (8-
pCPT-cGMP and 8-Br-cAMP). As expected, omitting of reagents led to decreased dif-
ferentiation in test conditions without addition of cGMP/cAMP-analogues (see Fig. 3.6).
As can be seen from Fig. 3.6, none of the tested conditions reached the same amount
of differentiation compared to standard differentiation, despite addition of promoters of
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preadipocyte differentiation. The combination that caused best results for differentiation
on an average was IBMX and dexamethasone + 8-pCPT-cGMP but this result did not
reach significance (see Fig. 3.6). Significant variation from controls (p≤0.05) was reached
in IBMX + dexamethasone, IBMX + dexamethasone + insulin with and without ad-
dition of 8-Br-cAMP. Weakest differentiation results were reached with the combination
of dexamethasone and insulin + 8-pCPT-cGMP (3,3% differentiated cells). Here, cyto-
toxic effects dominated in 2 of 3 patients although the concentration was the same as in
standard differentiation medium (1 mM).
3.5 Effect of clozapine on preadipocyte proliferation
Preadipocytes were cultured in DMEM/F12 with FCS and bFGF supplementation for
6 days. Clozapine, LiCl, and EGCG were added at concentrations indicated. The XTT
assay was applied after 2 and 4 days of proliferation. As can be seen from Fig. 3.7, growth
rates did not vary significantly from controls in any of the test conditions. The XTT assay
underlined the non-toxicity of the used reagents since each condition had about the same
amount of viable cells at each measurement (day 0, day 2, day 4).
3.6 Effect of clozapine and EGCG on preadipocyte
differentiation
To analyze the effect of clozapine and EGCG on preadipocyte conversion, differentiation
was induced at cell confluence. During the first 5 days of differentiation, clozapine, propo-
fol, LiCl, and EGCG were added at concentrations indicated. The extend of differentiation
was determined morphologically (Fig. 3.8) and on a molecular level (Fig. 3.9). As shown
in Fig. 3.8, controls (standard differentiation (A.), propofol (D.), and LiCl (E.)) showed
an almost equal amount of differentiated cells as indicated by intracellular fat vacuoles
which were seen in light microscopy (left column) and particularly marked after Oil Red
O staining (right column). Conditions treated with clozapine (B., C.) showed a higher
percentage of differentiated cells compared to controls, as confirmed by a larger number of
intracellular fat vacuoles in both light microscopy and Oil Red O staining. Also, a slightly
enhanced number of differentiated cells was found at 20 µM clozapine compared to 5 µM
clozapine, indicating a concentration-dependent enhancement of differentiation. Fig. 3.9
reveals the activity of GPDH in % compared to standard differentiation. Standard dif-
ferentiation was set 100% in order to standardize varying GPDH-activities from different
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patients. Both clozapine concentrations (5 µM and 20 µM) demonstrate a significant and
dose-dependent increase in GPDH-activity up to 30% (p ≤ 0.05). Propofol and LiCl did
not cause an increased GPDH-activity, they rather seemed to inhibit the differentiation
process. However, this observation was not confirmed by morphological findings (compare
Fig. 3.8). EGCG shows the most effective inhibition of GPDH-activity (approximately
85%, p ≤ 0.01). Cells treated with EGCG in combination with clozapine still demon-
strate a significant decrease in GPDH-activity compared to standard differentiation and
clozapine only treatment (p ≤ 0.05). This is supported by morphological findings, i.e.
less vacuoles and elongated cell shape (Fig. 3.9).
3.7 Intracellular effects of clozapine
Analyzing the molecular impact of clozapine on the redox status in preadipocytes, we
found no upregulation of Cu,Zn-SOD in the presence of clozapine but downregulation
of Mn-SOD at 5 µM clozapine (Fig. 3.10). In the presence of EGCG and clozapine
at the same time, however, expression of Mn-SOD was strongly upregulated whereas
Cu,Zn-SOD expression was not increased (Fig. 3.10. LiCl induced both Mn-SOD and
Cu,Zn-SOD which is consistent with the findings of Rodriguez de la Concepcion [176] in
brown adipocytes.
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Figure 3.2: Preadipocyte proliferation under NO-influence. Preadipocytes were treated
as described in Fig. 3.1. Instead of determining the amount of necrotic cells, proliferation was
evaluated every day by trypsinising cells and counting them under the microscope in a Neubauer
chamber (A.) or by performing XTT-assays (B.).
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A. 21.5 ± 5.2
C. 46.7 ± 4.3
B. 21.5 ± 4.2
D. 45.9 ± 7.2
Figure 3.3: Morphological analysis of NO effects on preadipocyte differentiation.
During the first 5 days of differentiation, DETA/NO or DETA were added at concentrations
indicated to confluent preadipocytes grown in standard differentiation medium. Shown here is
the morphological analysis of the influence of NO on preadipocyte differentiation after 14 days
without the addition of DETA/NO (A.), in the presence of DETA (B.), after treatment with
50 µM (C.) and 100 µM (D.) DETA/NO. Given in the right top corner of every picture is the
counted number of differentiated cells (±SD) as assayed after 15 days.
40 Chapter 3: Results
di
ffe
re
nt
ia
tio
n
[%
] c
om
pa
re
d
to
 
st
an
da
rd
tr
ea
tm
en
t
50
100
150
200
250
sta
nd
ard
dif
f.
+N
O7
0
+D
ET
A1
00
+N
O3
0
+N
O5
0
+N
O1
00
0
* * *
* *
Figure 3.4: GPDH-activity under the influence of DETA/NO and DETA.To deter-
mine the effect of NO on preadipoyte differentiation on an enzymatical level, cells were cultured
until confluence and differentiated as described above. During the first 5 days of differentia-
tion, DETA/NO was added at 30 µM (+NO30), 50 µM (+NO50), 70 µM (+NO70), or 100 µM
(+NO100) to the standard differentiation medium (standard diff.). DETA as control was applied
at 100 µM (Fig. 3.4). Given percental values are relative to standard differentiation treatment
which is set 100%. *, p≤0.05, **, p≤0.01
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Figure 3.5: GPDH-activity under the influence of activators/inhibitors of guanylyl
and adenylyl cyclase with and without DETA/NO-addition. To determine the ability
of each reagent to increase or inhibit preadipocyte differentiation, cells were cultured until
confluence and differentiated as described above. During the first 5 days of differentiation,
all reagents except DETA/NO at 70 µM (+NO70) - which was added on a daily base - were
added every second day to the standard differentiation medium (standard diff.). Given percental
values are relative to standard differentiation treatment which is set 100%. All values varied
significantly from the standard differentiation (p≤0.05) except for ODQ, ODQ + DETA/NO,
8-Br-cGMP + DETA/NO, 8-Br-pCPT-cGMP, DDA, DDA+ DETA/NO, and 8-Br-cGMP +
8-Br-cAMP.
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Figure 3.6: GPDH-activity of different culture media with or without addition
of cGMP/cAMP-analogues. Preadipocytes were differentiated under standard conditions
without addition of reagents (control) in standard differentiation medium or varied media as
indicated in the legend. cGMP and cAMP-analogues (8-pCPT-cGMP and 8-Br-cAMP) were
added at 1 mM every second day for the first 5 days of differentiation. Given percental values
are relative to treatment in standard differentiation which is set to 100%.
3.7 Intracellular effects of clozapine 43
control
cloz. 20 µM
LiCl
propofol
EGCG
EGCG+cloz. 20µM
Figure 1
ex
tin
ct
io
n 
(4
50
nm
)
days
700
600
500
400
300
200
100
0
900
800
0 2 4
control
cloz. 20µM
LiCl
prop fol
EGCG
EGCG + cloz. 20µM
Figure 3.7: Preadipocyte proliferation under the treatment of clozapine, propofol,
LiCl, and EGCG. Preadipocytes were grown in DMEM/Ham’s F12 medium with 10% FCS,
and bFGF, and clozapine, LiCl, and EGCG were added as concentrations indicated. The XTT
assay was carried out on days 0, 2 and 4. Shown are results from 3 individual experiments.
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A.
B.
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D.
Figure 3
E.
F.
10 µM EGCG
Figure 3.8: Morphological analysis of preadipocyte differentiation under clozap-
ine treatment. To analyze the effect of clozapine on preadipocyte differentiation, cells were
isolated, cultured until confluence and differentiated. Clozapine, propofol, LiCl, and EGCG
were added as indicated. After 8-12 days, the extend of differentiation was determined by light
microscopy in unstained (left column) or Oil Red O-stained (right column) cells. Shown are
representative light microscopy images from three individual experiments. A. control, B. 5 µM
clozapine, C. 20 µM clozapine, D. 10 µM propofol, E. 2 mM LiCl, F. 10 µM EGCG.
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Figure 3.9: Molecular analysis of preadipocyte differentiation under clozapine addi-
tion. Cells were treated as described in Fig. 3.8. After 14 days of differentiation, the extend of
preadipocyte conversion was determined by measuring GPDH activity relative to standard dif-
ferentiation which was set 100%. Results are from 7 individual experiments. cloz. = clozapine,
5 µM and 20 µM; propofol = 10 µM; LiCl = 2 mM; EGCG = 10 µM *, p ≤ 0.01 **, p ≤ 0.001
compared to standard differentiation
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Figure 3.10: Molecular analysis of preadipocyte proliferation under clozapine and
EGCG treatment. Preadipocytes were cultured as described before. The expression of Cu,Zn-
SOD and Mn-dependent superoxide dismutase (Mn-SOD) was determined by RT-PCR under
treatment with clozapine, EGCG, and LiCl. Shown is a representative agarose gel out of 3
individual experiments.
4 Discussion
4.1 Nitric oxide and adipogenesis
The role of nitric oxide in regulating biological functions including neurotransmission,
blood vessel tone, host defense, and immunity has become the focus of intensive research
throughout the last two decades [177, 178]. Its role in adipogenesis has been studied
by several groups focussing mainly on lipolysis and obesity mechanisms [113, 179–181].
Looking at the key features of adipogenesis - differentiation and proliferation - only a
few publications studied the effects of nitric oxide on differentiation and proliferation of
human preadipocytes in vitro: Yan et al. observed a promoting effect of nitric oxide on
differentiation in rat preadipocytes [107] which is consistent with the results in this thesis
for human preadipocytes. However, an inhibition of preadipocyte proliferation was not
found by Yan et al. in contrast to the findings in brown fat cells [182] and the results
presented here. Looking at eNOS and iNOS expression in differentiating cells, Yan et al.
confirmed the findings by Elizalde et al. [183], Ryden et al. [184], and Kikuchi-Utsumi
et al. [185]: both isoforms were present in differentiating preadipocytes. A more recent
study by Engeli et al. [115], however, found increased iNOS expression whereas eNOS
expression was not influenced.
Another aspect of this thesis was the detection of the intracellular cascade of nitric oxide
in preadipocytes. The main mechanism of intracellular NO-effects in most cells involves
the cGMP-cascade (see 1.4.1) which has been presented for NO in brown adipocytes by
Uchida et al. [165]. In brown adipocytes, NO is also known to up-regulate the expres-
sion of PPARγ [182]. Indeed, inhibition of guanylyl cyclase by ODQ caused a decreased
differentiation of preadipocytes in this study (Fig. 3.5). Nevertheless, the extend of this
inhibition is not able to explain the entire NO-effect whereupon we assumed other path-
ways might be involved, too. Apart from cGMP-independent pathways such as protein
modification by S-nitrosation of thiol groups (see 1.4.1), pathways involving adenylyl cy-
clase could also be a target of pro-adipogenic factors: pharmacological studies in cultured
cells show that, depending on the cell type examined, increased cAMP can exert opposite
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effects in gene expression and regulation of transcription factors including CREB and
C/EBP, being either stimulatory or inhibitory in adipocytes and other cells [186]. In this
context, the primary mechanism of cAMP-mediated action involves modulating effects on
iNOS-expression [186]. Since the main emphasis of this thesis was put on the effects of
added NO-donating agents rather than intracellular NO-production, I focussed primarily
on the potency of adenylyl-cyclase inhibitors such as 2’-5’-dideoxyadenosine (DDA)and
guanylyl cyclase inhibitors such as ODQ to reduce the effects of extracellularily added
NO. The inhibitory effects of DDA were not as distinct as with ODQ indicating that the
main mechanism involves the guanylyl cyclase rather than adenylyl cyclase (Fig. 3.5).
Addition of both inhibitors decreased differentiation to such a high extent that one has
to consider a strong involvement of both pathways in adipogenesis in general (Fig. 3.5).
However, the inhibitory effect of DDA could also be explained by the interruption of the
cAMP-induced modelling effects on intracellular iNOS expression thus decreasing NO-
release which could again promote differentiation via guanylyl cyclase. The exact role of
intracellularily released NO in adipogenesis was not part of this study but is worth being
studied further.
4.2 Inflammatory response
The above mentioned interrelations of nitric oxide and adipogenesis are also worth be-
ing discussed when considering inflammatory processes at the site of future implanta-
tion of preadipocyte-loaded scaffolds. Obesity is associated with inflamed adipose tissue,
which can be seen on a molecular level by decreased expression of the anti-inflammatory
adipokine adiponectin and increased secretion of a variety of proinflammatory cytokines,
e.g. tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, and prothrombotic factors
such as plasminogen activator inhibitor-1 (PAI-1) [117,119,187]. Also, the increased mass
of dysfunctional adipose tissue in obesity is known to be a source of several inflammatory
factors, including TNF-α, IL-6, and PAI-1 [188–191]. These proinflammatory molecules
have direct effects on adipose cell metabolism: TNF-α decreases insulin sensitivity and
promotes lipolysis [192, 193]. Adiponectin, in contrast, improves insulin sensitivity and
inhibits vascular inflammation [194–196]. TNF-α, IL-6, transforming growth factor beta
(TGF-β), and interferon gamma (INF-γ) have been described to be strongly mitogenic for
preadipocytes [197–200]. A more recent explanation of adipocyte-related inflammatory
processes was given by Weisberg et. al in 2003: they first described the role of adipose tis-
sue macrophages which strongly participate in inflammatory pathways [201]. The adipose
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tissue of obese mice had an increased number of macrophages which were later demon-
strated to impair adipogenesis via lipolytic activities and moreover seemed to produce the
main fraction of inflammatory molecules in the adipose tissue [202,203]. In vitro, inflam-
mation induced by zymosan (a polysaccharide of the cell wall of saccaromyces cerevisiae
bacteria [204]) does not only activate macrophages and neutrophils [205,206], it has also
been shown to interact with preadipocytes [207]. In macrophages, contact with zymosan
particles activates NF-κB which leads to the production of cytokines. Hemmrich and
Thomas recently showed that zymosan treatment of preadipocytes also led to increased
TNF-α levels and promoted adipogenesis at an early stage [116]. The mechanism behind
is believed to be linked to increased iNOS-expression. iNOS is one of the key effector
enzymes in inflammation which is inducible by various inflammatory cytokines and is a
downstream target of NF-κB [208–212] (see 1.4.2). Furthermore, Chung at al. assumed
that preadipocytes are in truth responsible for the recruitment of monocytes/macrophages
via MCP-1 and are moreover able to generate inflammatory signals thereby inhibiting
PPARγ expression and insulin sensitivity in adipocytes [213]. Thus, there is a strong
cross-link between preadipocyte and macrophage activation. Preadipocytes also express
receptors for inflammatory chemokines [214] and migrate in response to them [215]. The
above mentioned MCP-1 is one of these chemokines to which preadipocytes express re-
ceptors [214]. MCP-1 is secreted by mature adipocytes in obesity and the metabolic
syndrome [58,216,217]. Hemmrich and Thomas just confirmed its adipogenesis-inducing
abilities [116]: preadipocytes migrated in response to MCP-1 and other macrophage di-
recting chemokines therefore allowing adipogenesis even in the absence of pre-existing fat.
Although the maintenance of a chronic low-grade inflammation state and higher expres-
sion of iNOS, TNF-α, Il-6, and CRP in the adipose tissue are generally linked to the
progression of obesity [117,218–220], one has to be cautious to assume a general positive
correlation between inflammation at the site of the transplant and adipogenesis: TNF-α,
IL-6, transforming growth factor β (TGF-β), and interferon γ (INF-γ) have been shown
to inhibit preadipocyte differentiation and lipid accumulation [197,198,200,221,222]. An-
other hypothesis regarding the cross-link between inflammation and obesity is the notion
that inflammation can be seen as an adaptive response to hypoxia in the expanding fat
tissue [223]: hypoxia causes HIF-1-mediated PPARγ repression (see 1.3.2) which lim-
its further adipogenesis. Hemmrich and Thomas also observed inhibitory processes due
to inflammation in the final phase of adipogenesis [116]. In this study, however, the
proinflammatory molecule NO strongly promoted adipogenesis. Since NO shows a high
diversity in influencing intracellular pathways, one cannot exclude that it plays an ex-
ceptional role in preadipocyte differentiation. These results have been confirmed by the
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findings of Hemmrich and Thomas [116]: they observed reduction of adipogenic response
of over 50% when NO-production was blocked. Inflammation at an early stage of adipo-
genesis even induced de novo endogenous adipogenesis and preadipocyte migration.
These observations have to be brought to mind when future transplantations of adipose
tissues are planned. Inflammation at the site of the transplant might be detrimental or
beneficial, depending on the amount and composition of inflammatory molecules. Fur-
ther in vivo research is therefore necessary. A possible application of NO-donors can
however stimulate preadipocyte differentiation. Nevertheless, the inhibitory effect of NO
on preadipocyte proliferation should be considered when applied at an early state of cell
proliferation: the NO-effect might be detrimental for a transplant without complete cell
congruency. If preadipocytes ought to be seeded onto three-dimensional carriers, they
should therefore undergo a long proliferating phase until being attached to other cells
before NO addition. Imaginable would be NO-addition at a state of cell congruency
in vitro or after implantation in vivo therefore allowing a more effective differentiation
process especially in larger transplants. However, the positive effect of NO on vessel
formation [224–226] (see section 4.3) would have to be taken into consideration when
outweighing the advantages and disadvantages of late NO application.
4.3 ”Side-effects” of NO: promotion of angiogenesis and
cell survival
Another limitation of current adipose tissue engineering applications is the insufficient
vascularization and hypoxic conditions of the three-dimensional constructs, especially in
the center. Although NO-effects on endothelial cells were not part of this study, this topic
has to be considered in the context of improving and understanding angiogenesis. The
key molecule in angiogenesis, as well as in vasculogenesis during embryonic development,
is VEGF which can be induced by a number of angiogenic stimuli such as cytokines,
hormones, and hypoxia [227]. Most embryonic vessels and endothelial cells express re-
ceptors for VEGF. In the last 10 years, more and more evidence emerged that VEGF
and VEGF-related pathways are also inducible by NO-donors [102, 228]. Yet, only a
certain amount of NO will upregulate VEGF gene expression while an excessive dose of
NO inhibits VEGF expression via unidentified pathways [229]. Furthermore, VEGF may
activate eNOS expression in endothelial cells [230]. The resulting NO will then in turn
mediate the angiogenic effects of VEGF [224–226]. This VEGF-mediated NO synthe-
sis is due to an immediate pathway via phosphorylation of eNOS and a delayed effect
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causing both phosphorylation and upregulation of eNOS [231–234]. Apart from VEGF,
expressional increases by NO have also been shown for bcl-2 expression at the mRNA
and the protein level [235–239]. Bcl-2, a stress response gene, is a potent apoptosis onset
inhibitor [238]. The balance between the anti- and pro-apoptotic proteins of the bcl-2
family of proteins regulate cell death and cell survival. The exact mechanisms are still
unclear but some groups relate them to the ability of the bcl-2 family proteins to form ion
channels and complexes with other proteins [240–244]. The most common hypothesis re-
garding the cell stabilizing effect of bcl-2 involves prevention of mitochondrial cytochrome
c release [245–248]. This model was also confirmed by Hemmrich et al. in 2003 [249] in
antisense-mediated iNOS-knockdown in endothelial cells: these cells were more suscepti-
ble to reactive-oxygen species-mediated cell death which elucidates the pivotal role of NO
in bcl-2 expression. A more recent study by Hida et al. in 2004 [250] combines the role
of NO in the expression of VEGF and bcl-2: their in vitro results confirm the promoting
effect of NO on endothelial cell proliferation and angiogenesis as well as its protective
ability against apoptogenic agents. Summarizing these observations, NO-donating agents
- when used with care - may not only enhance the differentiation of adipogenesis in the
implant but also improve vascularization and resistance against hypoxic conditions by
upregulating VEGF and bcl-2 expression.
4.4 Optimization of preadipocyte culture conditions
A thorough understanding of the differentiation process of preadipocytes is necessary
to improve and facilitate culture conditions. Fig. 1.8 summarizes effectors and possible
mechanisms of adenylyl and guanylyl cyclase-dependent cascades. Although Ibrahimi et
al. [251] postulate a decreased differentiation process under elevated intracellular cAMP-
levels, most studies agree to the pro-adipogenic potential of cAMP [163,164]. Its potency
to induce CREB has already been described by Roesler et al. [252] about 20 years ago. A
more recent study underlines the pivotal role of CREB in initiating preadipocyte differ-
entiation [164]. Moreover, cAMP itself seems to activate the expression of stearoyl-CoA
desaturase gene 1 thereby stimulating this fatty acid-modifying enzyme which is involved
in differentation by producing monosaturated fatty acids from saturated precursors [163].
Yet, the role of cAMP in adipogenesis and lipolysis seems to be paradoxical: some labo-
ratories found increased lipolysis after stimulation of cAMP-PKA [253–255] and even de-
creased obesity in PKA knockout-mice [256]. These controversial results may be explained
by the complex mechanisms of cAMP on the one hand and by different study designs on
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the other hand: cAMP and PKA regulate various intracellular systems (not just CREB)
and, vice versa, CREB may not alone be influenced by cAMP but by numerous growth
factors [257, 258]. cAMP-PKA signaling may also depend on the stage of adipocyte dif-
ferentiation: other PPARγ agonists such as FK614 (3-(2,4-dichlorobenzyl)-2-methyl-N -
(pentylsulfonyl)-3-Hbenzimidazole-5-carboxamide) have differentiation stage-dependent
effects which contribute to an enhanced insulin sensitization in differentiating adipocytes
and to reduced insulin resistance at the stage of adipocyte hypertrophy [259]. In conclu-
sion, although cAMP induces differentiation from preadipocytes to adipocytes, its effect
on lipid metabolism in mature adipocytes may be totally different. The results of this
study support the pro-adipogenic model of cAMP in early differentiation: the adenylyl cy-
clase activator forskolin as well as cAMP-analogues (8-Br-cAMP) and inhibitors of PDEs
(IBMX) enhanced differentiation to a high extent (Fig. 3.5). All reagents were added
for the first 5 days of differentiation where they seemed to have the best differentiation-
stimulating abilities, which is consistent with the above mentioned interrelations.
Besides cAMP, cGMP and NO also present potent stimulators of differentiation. The
intracellular actions of NO are described more thoroughly in the section 4.1. In this
context, the guanylyl-cyclase dependent pathway is of special interest. cGMP and its
potency to enhance preadipocyte differentiation has rarely been studied. Phosphoryla-
tion of protein kinases, however, plays a major role in regulating transcription factors
in other cell types [260–262], which also includes activation of CREB [263]. Thus, both
adenylyl and guanylyl-dependent pathways may end in similar phosphorylation activities,
at least to some extent (see also Fig. 1.8) which explains their synergistic effects shown
in this study (see Fig. 3.5). A combination of NO with activators of adenylyl cyclase and
analogues of cGMP and cAMP resulted in an even faster differentiation process. Neverthe-
less, one should be cautious with combinations of all reagents since overstimulation often
caused poorer differentiation especially in more susceptible cells (as could be observed in
some samples that derived from liposuction which were not included in this study). My
observations can be helpful in tissue engineering in terms of in vitro enhancement of dif-
ferentiation before transplantation of adipose tissue grafts or even in vitro using cGMP- or
cAMP-donating agents. By omitting certain reagents in the culture medium and replac-
ing them with more potent reagents (NO, forskolin, and analogues of cAMP or cGMP),
the whole culturing process can be facilitated in general which might also be helpful
for further research on preadipocytes in other contexts. Unfortunately, most combina-
tions resulted in poorer differentiation-processes compared to the standard differentiation
medium (Fig. 3.6). Thus, it remains questionable if this type of medium variation will
prevail in preadipocyte culturing since it led to rather cytotoxic effects in some patients
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which might explain the high standard deviation and low significance. IBMX seemed to
have the strongest differentiation-promoting effect since ommitting of this reagent led to
poor results for differentiation (see Fig. 3.6) whereas addition often caused overstimulation
and cytotoxy in combination with cGMP/cAMP-analogues. These results are controver-
sial at times, since a combination of IBMX, insulin, and cGMP/cAMP-analogues always
led to cytotoxic effects even though the concentration of all reagents was not changed.
Also, the combination of IBMX, dexamethasone, and insulin together with these activa-
tors showed weaker GPDH-activities than the combination of IBMX and dexamethasone
alone. Thus, the particular balance of activators of differentiation might be an underes-
timated factor. Maybe a reduction of IBMX-concentration in the media could present a
basis for further research since the cells seemed to be stressed (seen by changed cell shape)
in test conditions with IBMX without ”outbalancing” factors as can be found in the stan-
dard differentiation medium. I therefore conclude that the most effective differentiation
was still observed in standard differentiation medium with added promoters of differen-
tiation such as cGMP/cAMP-analogues, forskolin, and NO. If time is more important, I
would recommend continuing preadipocyte differentiation under these circumstances. If
incomplex experiment set-ups are needed - as in adipose tissue engineering - a modified
medium containing DMEM/Ham’s F12, IBMX and dexamethasone plus cAMP or cGMP
analogues could represent an adequate alternative to the standard if IBMX-concentration
is reduced (follow-up experiments needed).
4.5 Effects of clozapine and green tea on adipogenesis
Weight gain is a common complication of antipsychotic treatment starting a few months
after initiation of therapy [127]. Common hypotheses for the pro-adipogenic effect of
clozapine involve CNS-based neuroendocrine circuits regulating the interaction of lep-
tin, ghrelin, and adiponectin. All three hormones play a major role in the regulation
of energy homeostasis and food intake [133, 264]. However, so far, results concerning
clozapine-related weight gain remain controversial: Atmaca et al. observed significant
increases of plasma triglyceride and leptin levels in patients treated with clozapine sug-
gesting a positive correlation between leptin and weight gain [132]. In contrast, Albaugh
et al. found lowered plasma levels of glucose and leptin in rats under treatment with
olanzapine whereas clozapine did not show this effect [265]. Also, some studies aimed at
explaining the clozapine-induced weight gain by increased plasma levels of insulin, ghrelin,
and adiponectin: in their cross-sectional study, Togo at al. found no significant increase
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in serum ghrelin levels in patients treated with clozapine compared to healthy individu-
als [134]. The same observation was made by Theisen et al. [266] in a prospective study
whereas Hosojima et al. [135] report a decreased serum ghrelin level in patients treated
with olanzapine and clozapine as well as unchanged adiponectin and insulin plasma levels.
These discrepancies might be explained by different study designs, application of different
neuroleptics, different lengths of observation, and numbers of patients. Still, on the basis
of all literature reports, there is no definite correlation between weight gain and plasma
levels of hormones regulating energy homeostasis. Another focus of attention in the con-
text of neuroleptics-induced weight gain are genetic polymorphisms as found for various
ligands, such as second messengers coupled to the serotonin (5HT) receptor [267] or di-
rect binding of atypical neuroleptics to receptors that regulate weight [265]. Again, these
studies have not yet found a plausible explanation for weight gain in patients. The fact,
that even strict diets are unable to stabilize body weight points towards other mechanisms
to be the cause of the observed weight gain. This study suggests fat neo-formation as
the key mechanism for weight gain. I found a significant increase of 30% in preadipocyte
differentiation under clozapine treatment compared to controls. I propose that the effect
of clozapine on preadipocyte differentiation relies on the intracellular localization of the
drug. Clozapine preferentially accumulates in lipid membranes where it acts as an excel-
lent radical scavenger [268].
The redox metabolism in cells corresponds to a complex interacting network involving
the generation of reactive oxygen species and cellular antioxidant defenses (see also chap-
ter 1.3.3) [84]. Any disturbance of this balance can induce several transduction pathways
and transcription factor activities, e.g. erythropoietin and vascular endothelium growth
factor gene transcription [74,84].
Carriere et al. demonstrated that propofol induces preadipocyte differentiation by radi-
cal scavenging [74, 83]. I propose the same effect for clozapine. Fig. 4.1 summarizes the
proposed interrelations between ROS production, clozapine, and EGCG. Increased mi-
tochondrial ROS production can be eliminated by upregulation of Mn-SOD. This seems
to be exactly the pathway, EGCG uses to counteract clozapine-induced differentiation.
In clozapine-treated preadipocytes, Mn-SOD expression is significantly induced in the
presence of EGCG (Fig. 3.10) and the resulting hydrogen peroxide inhibits further differ-
entiation (Fig. 4.1). EGCG-mediated upregulation of Mn-SOD and subsequent hydrogen
peroxide production has previously been observed in cancer cells which contain higher
levels of superoxide [162, 269]. Thus, EGCG has pleiotropic effects with mechanisms
of action that include working as an antioxidant or a pro-oxidant [269]. In the pres-
ence of clozapine, EGCG appears to function as a pro-oxidant that induces NF kappa
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free radicals, 
H2O2
preadipocyte differentiation
Superoxide anions
Figure 4.1: Proposed scheme of the influence of clozapine and EGCG on adipoge-
nesis. Clozapine promotes radical scavenging leading to enhanced preadipocyte maturation.
EGCG inhibits clozapine-enhanced differentiation by induction of Mn-SOD. The resulting prod-
uct H2O2 inhibits preadipocyte differentiation.
B activation [270] and subsequent Mn-SOD expression. In line with my results that
Mn-SOD activity prevents preadipocyte differentiation, Lechpammer et al. [271] reported
that Mn-SOD-/- bone marrow stromal cells demonstrate constitutive adipocytogenesis
and generate 34% more adipocytes in differentiation medium than Mn-SOD+/+ cells.
Moreover, Mn-SOD polymorphisms have been described, that might contribute not only
to clozapine-involved weight gain. Recently, Galecki et al. reported a Val-9Val genotype
of the Mn-SOD gene that is associated with a three times higher risk for schizophre-
nia [272]. This mutation influences the mitochondrial targeting of the enzyme and leads
to enhanced oxidative stress associated with schizophrenia [273]. I speculate that the ben-
eficial effects of clozapine treatment are at least partially based upon its radical scavenging
capacity. Nevertheless, the intracellular mechanisms of oxidative stress are complex pro-
cesses involving cell-specific coping with superoxide anions and other free radicals. In
contrast to Carriere et al. and contrary to my assumption, propofol did not increase
differentiation of preadipocytes by decreased hydrogen peroxide levels and free radical
scavenging. This observation might be due to different susceptibility of differentiating
human preadipocytes to propofol (in contrast to preadipocyte cell-lines as being used by
Carriere et al.) and different experimental set-ups (8-12 days of differentiation prior to
GPDH-assay compared to 96 hours in the set-up of Carriere et al.). My results might be
more significant since the differentiation process was assessed for a longer time-interval
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and was documented morphologically, too. Nevertheless, this fact does not explain the
controversial issue around oxidative stress and propofol, the most supposable explanation
could be the neglectable propofol-stimulus in the complex mechanism of preadipocyte
differentiation in my experiments whereas clozapine presented a stronger stimulus. The
influence of oxidative stress on fat cell formation is seen controversially in the literature,
too: clinical studies postulate a correlation of decreased plasma antioxidants with obesity
prevalence [274] suggesting that oxidative stress promotes adipogenesis. Moreover, Fujita
et al. associated increased systematic oxidative stress with visceral fat accumulation and
metabolic syndrome [275]. Nevertheless, these studies regarded systemic markers rather
than intracellular redox changes and are therefore less concerned with processes directly
linkable to the adipose tissue. Also, this study is not the first to describe clozapine-
treated preadipocytes: in 2003, Hauner et al. investigated the effects of clozapine on
mammary adipose tissue and found no increased fat cell formation [276]. Neither pro-
liferation nor differentiation of preadipocytes was enhanced under clozapine-treatment.
The fact that these findings are contradictory to mine might be explained by the at-
tributes of the mammary tissue which was the only tissue source used by Hauner et al.
and the low number of tested tissue specimens. My adipose tissue samples were derived
from abdominoplasty operations since abdominal fat cells have a higher susceptibility
to hormonal stimulation and are therefore more suitable for research on preadipocyte
differentiation [277, 278]. However, the in vitro enhancement of preadipocyte differen-
tiation of approximately 30% does not completely explain the immense weight gain in
patients. Considering intraindividual differences in long-term studies [131], multifactorial
influences such as genetic predisposition and comorbidity might also contribute to the
extent of weight gain. Still, my results present an easy and effective way to prevent the
clozapine-induced weight gain to some extent. EGCG in green tea or in form of capsules
could counteract the enhancement of differentiation since my in vitro results suggest that
it effectively prevents preadipocyte differentiation by upregulating Mn-SOD(Fig. 3.10),
causing higher concentrations of hydrogen peroxide. EGCG is also known to reduce levels
of adipogenesis-related transcriptional factors, such as C/EBPβ and PPARγ [158], and to
suppress the activation of enzymes responsible for lipid metabolism, e.g. sterol regulatory
element binding protein-1 (SREB-1), in adipose tissue [159]. Various studies show that
EGCG reduces size and number of lipid droplets and GPDH-activity in differentiating
preadipocytes [160]. Although clinical data have so far shown little potency of EGCG
on weight reduction in obese people, in vitro studies and animal trials have repeatedly
demonstrated its anti-adipogenic effect [158–160]. Recent studies on olanzapine-induced
weight gain undertaken in the USA [126] and China [279] reveal a medium weight gain
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of 15.4 ± 10 kg in American people versus 8.34 ± 5.97 kg in Chinese patients after 2
years of treatment. This striking discrepancy may indicate that the high consumption of
green tea in China is involved in the decreased weight gain under therapy with atypical
neuroleptics. Thus, EGCG presents an easily applicable and promising tool in treating
clozapine-induced weight gain by counteracting clozapine-mediated preadipocyte differ-
entiation and by general inhibition of lipid metabolism. Moreover, due to the general
beneficial effect of green tea on health, EGCG treatment may be useful to prevent the
metabolic disturbances often leading to the metabolic syndrome under clozapine treat-
ment [160].
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5 Conclusion
The findings of this study extend the understanding of how NO plays a significant role
in regulating proliferation and differentiation of human preadipocytes. This is helpful to
modify present tissue engineering applications in order to improve cell maturation and
organization in three-dimensional biohybrids by applying nitric-oxide donating agents in
vitro and in vivo. Furthermore, the findings on optimizing and facilitating preadipocyte
culture may be useful in further research on adipogenic precursors, in tissue engineering as
well as in reasearch on obesity or adipose-tissue related diseases: the culture medium was
modified to such an extent that the differentiation process from preadipocytes to mature
fat cells was shortened from 14 days to 8-10 days on an average. An alternative culture
medium was also presented in using the formerly applied reagents of the standard medium
substituted with potent activators of adenylyl- or guanylyl-cyclase-dependend pathways
thereby facilitating experimental set-ups. In a second study, the intracellular mechanisms
of clozapine and EGCG on preadipocyte proliferation and differentiation were evaluated.
The findings support the hypothesis of a proadipogenic clozapine effect which can be
counteracted by EGCG. This is most likely due to the radical scavenging abilities of
clozapine which favour preadipocyte differentiation probably independent from receptor-
activated pathways. The proadipogenic effects of clozapine lead to an enlarged fat mass
which is detrimental in clozapine-therapy since it impairs health status and compliance
of treated patients. EGCG could be a potential remedy by up-regulating Mn-SOD and
inhibiting preadipocyte differentiation in general. Drinking green tea might therefore
be an easy but effective way to reduce the clozapine-induced weight gain. This study
gives an example of possible mechanisms but might not completely explain the entire
extent of clozapine-induced enhancement of preadipocyte differentiation. That is why
further studies are needed to outline alternative intracellular mechanisms elucidating the
complex mechanism of intracellular clozapine-effects more thoroughly.
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Abstracts
Optimized adipose tissue engineering with the use of nitric
oxide-donating agents
C. Gummersbach, K. Hemmrich, M. Meersch, N. Pallua, Department of Plastic Surgery
and Hand Surgery - Burn Center, University Hospital of the Aachen University of Technology,
Germany
Introduction: Nitric oxide (NO) has multiple effects on cellular pathways of human
cells. This study focusses on the impact of NO in adipose tissue engineering and inflam-
matory processes after transplantation of soft tissue grafts. These grafts represent an
adequate option to correct soft tissue defects resulting from deep burns, tumor resections
or congenital defects. Analyzed in this study are the effects of NO on the proliferation
and differentiation of preadipocytes, progenitor cells with stem-cell characteristics, within
the adipose tissue. The aim is to optimize adipose tissue engineering and to anticipate
possible complications due to inflammatory reactions in wound situations after transplan-
tation.
Materials & Methods: Preadipocytes were isolated from human subcutaneous adipose
tissue samples and cultured in Dulbecco’s modified Eagle medium (DMEM)/F12 (1:1)
with 10% fetal calf serum (FCS). Cells were grown in bFGF (basal fibroblast growth
factor)-supplemented medium with the NO donor molecule DETA/NO added at various
concentrations for proliferation and differentiation. Differentiation was induced by in-
suline, isobuthylmethylxanthine, pioglitazone, dexamethasone and transferrin after 7-14
days of culture expansion and in absence of FCS. Proliferation was analyzed by microscopy
and by XTT-tests which determine the absorbance of a formazan dye which can only be
produced by viable cells. Differentiation of preadipocytes was assayed after 15 days by
cell counting and analysis of the enzyme glycerophosphate dehydrogenase which is highly
expressed in mature adipocytes.
Results: Our results show a significant inhibition of preadipocyte proliferation in the
presence of NO. Further, we observe an enhanced maturation of precursor cells to mature
fat cells in the presence of DETA/NO. NO also increases the number of differentiated cells
if adipogenic conversion is only promoted by dexamethasone, insuline and transferrin.
Discussion & Conclusion: Our results emphasize the important role of NO in tis-
sue engineering and are encouraging for applying NO-donors during transplantation of
preadipocytes in a three-dimensional setting since it helps optimizing differentiation of
adipogenic precursor cells. Thus, NO-supplemented implants open new perspectives for
adipose tissue engineering to treat extended soft tissue defects.
Enhancement of differentiation of progenitor fat cells: a possible
mechanisms of clozapine-induced weight gain
C. Gummersbach1, K. Hemmrich1, N. Pallua1, K. Fehsel2
1Department of Plastic Surgery and Hand Surgery - Burn Center, University Hospital of
the Aachen University of Technology, Germany
2Heinrich-Heine-University of Du¨sseldorf, Germany
Introduction: Psychoactive drugs and especially clozapine cause massive weight gain
in patients. Recent studies focussing on the activation of neuropeptides which are in-
volved in the appetite regulating network presented controversal results. We postulated
a direct effect of clozapine on fat cells. Therefore we studied the influence of clozapine
on progenitor fat cell differentiation to mature adipocytes leading to increased fat mass.
Moreover, we tried to find out if extract from green tea (EGCG) which is known to in-
hibit the formation of triglyceride vesicle formation could prevent the clozapine-induced
differentiation process.
Materials & Methods: Preadipocytes were isolated from human subcutaneous adi-
pose tissue samples and cultured in Dulbecco’s modified Eagle medium (DMEM)/F12
(1:1) with 10% fetal calf serum (FCS). Differentiation was induced by insulin, isobuthyl-
methylxanthine, pioglitazone, dexamethasone and transferrin after 7-14 days of culture
expansion and in absence of FCS. Clozapine, EGCG and LiCl were added every second
day for the first 5 days of differentiation. LiCl, a mood stabilising drug, served as control
since it induces weight gain as well but through different mechanisms such as glucocorti-
coid elevation. Differentiation was assayed after 8-15 days by cell counting and analysis
of the enzyme glycerophosphate dehydrogenase highly expressed in mature adipocytes.
We also examined the effects of oxidative stress, the rate of apoptosis and PCR analysis.
Results: Treatment of preadipocytes with clozapine induced a significant rise in GPDH
activity and an elevated number of differentiated cells. Lithium chloride showed no dif-
ference compared to standard differentiation. Extract from green tea (EGCG) inhibited
differentiation in general but also under clozapine treatment.
Discussion & Conclusion: Our results suggest a new explanation of weight gain in pa-
tients treated at least with clozapine: increased fat mass due to enhanced differentiation
from progenitor fat cells to mature adipocytes. EGCG could help preventing this weight
gain. We speculate that the enhanced differentiation might be caused by oxidative stress
or the involvement of cGMP.
Green tea extract presents new options to manage weight gain
under psychopharmacotherapy
C. Gummersbach1, K. Hemmrich1, N. Pallua1, K. Fehsel2
1Department of Plastic Surgery and Hand Surgery - Burn Center, University Hospital of
the Aachen University of Technology, Germany
2Heinrich-Heine-University of Du¨sseldorf, Germany
Introduction: Atypical neuroleptics such as clozapine and olanzapine have essentially
improved the treatment of schizophrenia. Unfortunately, both drugs lead to an excessive
weight gain in patients which reduces their compliance and also bears a risk for their
physical health. Trying to find an explanation for the clozapine-induced weight gain,
many studies presented controversial results for hormones involved in energy homeosta-
sis, such as leptin or insulin. Focussing on a completely different aspect, we examined the
effect of clozapine on the differentiation process from adipogenic precursor cells, called
preadipocytes, to mature fat cells. We further studied possible intracellular mechanisms
to find an effective remedy. Since cellular redox status and free radical formation are po-
tent regulators of adipogenic conversion, we looked at the ability of extract from green tea
(EGCG) to inhibit preadipocyte differentiation, thereby counteracting the pro-adipogenic
effect of clozapine.
Methods: Preadipocytes were isolated from human subcutaneous adipose tissue sam-
ples and cultured in Dulbecco’s modified Eagle medium (DMEM)/F12 (1:1) with 10%
fetal calf serum (FCS). Differentiation was induced by insulin, isobuthylmethylxanthine,
pioglitazone, dexamethasone, and transferrin after 7-14 days of culture expansion and
in absence of FCS. Clozapine, EGCG and LiCl were added every second day for the
first 5 days of differentiation. LiCl, a mood stabilising drug, served as control since it
induces weight gain as well but through different mechanisms such as glucocorticoid ele-
vation. Adipogenic conversion was determined by measuring GPDH activity and Oil Red
O staining. Cellular redox status was determined by superoxide radical formation and
PCR-analysis of enzymes involved in reactive oxygen species formation (ROS).
Results: We found that clozapine-enhanced fat neo-formation is based on the ability
of clozapine to scavenge free radicals, therefore reducing oxidative stress which favours
preadipocyte differentiation. Green tea extract (EGCG) effectively inhibited clozapine-
enhanced differentiation by strong induction of a key regulator in ROS-formation, Mn-
superoxide dismutase (Mn-SOD). Mn-SOD converts superoxide anions to hydrogen per-
oxide which inhibits further differentiation from preadipocytes to mature fat cells.
Conclusions: Our findings indicate that the long-lasting, constant clozapine-induced
weight gain is due to the powerful radical scavenging capacity of clozapine. This leads
to an enhanced differentiation process from immature fat cells to adipocytes resulting in
an enlarged fat mass. EGCG was able to efficiently prevent this detrimental process and
could therefore present a promising tool to avoid weight gain under therapy with atypical
neuroleptics.
Preadipocyte differentiation is enhanced by the signaling
molecules nitric oxide, cGMP and cAMP - new options for old
hurdles in adipose tissue engineering
C. Gummersbach1, K. Hemmrich1, M. Meersch1, N. Pallua1
1Department of Plastic Surgery and Hand Surgery - Burn Center, University Hospital of
the Aachen University of Technology, Germany
Background: This study aimed at analyzing the effects of nitric oxide (NO) on
preadipocytes in a setting as found after transplantation of a biohybrid composed of viable
adipose precursor cells and a three-dimensional matrix. Such an implant potentially repre-
sents an adequate solution for the correction of soft tissue defects, e. g. extensive deep
burns or tumor resections. The function of NO in such a setting of adipose tissue genera-
tion has not been monitored yet. Besides its important role in regulating physiological and
pathophysiological functions throughout the body, NO represents an early consequence
and marker of proinflammatory reactions as found in wound situations after transplanta-
tion. A present focus of attention in tissue engineering is the insufficient maturation of
preadipocytes which results in cell necrosis and fibrotic tissue formation, especially in the
center of larger three-dimensional constructs. A transplanted preadipocyte-loaded scaffold
with these attributes will not meet the requirements for modelling and refilling extensive
soft tissue defects. Optimizing preadipocyte culture and differentiation is therefore cru-
cial to overcome complications at the site of the transplantation. In this study, human
preadipocytes were treated with the NO donor DETA/NO and its down-stream signalling
molecules cGMP and cAMP to analyze the signalling pathway of NO in preadipocytes
and to optimize adipogenic conversion to mature fat cells.
Methods: Preadipocytes were isolated from human subcutaneous adipose tissue sam-
ples and cultured in Dulbecco’s modified Eagle medium (DMEM)/ Ham’s F12 with 10%
FCS. At confluence, differentiation was induced by insulin, pioglitazone, dexa-methasone,
isobutylmethylxanthine, and transferrin in the absence of FCS. To further identify the
molecular pathway, by which NO mediates its effect, the specific guanylyl cyclase inhibitor
ODQ, the adenylyl cyclase inhibitor 2’-5’-dideoxy-adenosine, the cGMP and cAMP-
analogues 8-Br-cAMP and 8-Br-cGMP, and the adenylyl cyclase activator forskolin were
added. Proliferation was evaluated by microscopy and XTT-assays while differentiation
was assessed by cell counting and analysis of the enzyme glycerophosphate dehydrogenase.
Results: Our results demonstrate that NO in combination with the conventionally used
differentiation-inducing factors significantly (p¡0.01) enhances maturation of precursor
cells to adipocytes via guanylyl cyclase dependent pathways but also - to a certain extend-
via adenylyl cyclase dependent pathways. The combination of NO with activators of
adenylat cyclase and cGMP-/cAMP-analogues results in a significantly accelerated and
enhanced differentiation process (p¡0.05). Proliferation, in contrast, is inhibited in the
presence of NO.
Conclusion: Our results help to understand the possible effects of inflammation in a
preadipocyte-seeded tissue construct. NO-release as a consequence of inflammatory pro-
cesses will be beneficial at cellular confluence to substantially induce preadipocyte dif-
ferentiation. Before confluence is reached, though, an inflammatory stimulus might be
detrimental as it strongly inhibits preadipocyte proliferation. Our findings are encourag-
ing for applying NO-donors and activators of cAMP/cGMP-dependent pathways during
transplantation of preadipocytes in a three-dimensional setting to accelerate and opti-
mize differentiation of preadipocytes. Furthermore, the results are helpful for modifying
present tissue engineering applications in order to improve progenitor cell maturation and
cell organization in three-dimensional biohybrids.
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